Chemours Company (CC)

Chemours Reaches Agreement with U.S. EPA to Resolve Claims Relating to PFASJune 24, 2026 10:43 AM
PR Newswire (US) The settlement resolves the federal government's claims relating to discharge of PFAS compounds across three current operating sites, as well as certain environmental claims by the State of West Virginia.  Chemours is expected to pay EPA and WVDEP a $22.5 million civil penalty over a three-year period, and fund $90 million in additional mitigation projects over the next 15 years to further reduce PFAS emissions and enhance certain existing off-site drinking water programs.The settlement recognizes that Chemours has already begun planning and implementing operational improvements and remedial measures at its facilities, and contains further actions the Company will take to mitigate future emissions and enhance existing programs.This settlement provides Chemours with greater clarity on future compliance requirements and actions to support long-term responsible manufacturing.WILMINGTON, Del., June 24, 2026 /PRNewswire/ -- The Chemours Company (NYSE: CC) (the "Company") today announced a settlement to resolve claims asserted by the U.S. Environmental Protection Agency ("EPA") relating to PFAS discharges and other alleged non-compliance actions, primarily at the Company's Washington Works, Fayetteville Works, and Chambers Works facilities. The West Virginia Department of Environmental Protection ("WVDEP") is also a party to the settlement and joins in these releases.The settlement agreement is the latest progress delivered under the Strengthening the Long Term pillar of Chemours' Pathway to Thrive strategy, which includes the Company's sustained efforts to address legacy PFAS and other environmental claims. The settlement also recognizes the significant work already completed or underway across Chemours' sites to reduce emissions and strengthen processes.Under the settlement, Chemours has agreed to pay EPA and WVDEP a $22.5 million civil penalty, of which $15 million was previously accrued. This civil penalty is expected to be paid in three annual installments in 2026, 2027 and 2028, beginning within 30 days of the court's approval of the Consent Decree containing the settlement. In addition, over the next 15 years, Chemours will fund $90 million in additional mitigation projects to further reduce PFAS emissions from the operating sites or drinking water projects. Such projects support Chemours responsible manufacturing practices and will help advance the Company's Corporate Responsibility Commitment goal to reduce process emissions of fluorinated organic chemicals by 99% or more by 2030.Further, the Company has also agreed to perform certain program and site-related actions as part of the settlement. This includes an expansion of the Company's existing off-site drinking water programs in West Virginia, Ohio, and New Jersey to incorporate learnings from Chemours' other off-site programs. The Company expects the expansion of the off-site drinking water programs will result in an increase to its existing environmental reserves.Aligned with the Company's Pathway to Thrive strategy, Chemours continues to focus on responsibly resolving outstanding environmental and regulatory matters with terms that improve site operating certainty and include payment and remediation commitments that are structured over time. The terms of the settlement, including a further description of claims released and not released, are set forth in a proposed Consent Decree, which remains subject to final court approval.In connection with the settlement, Chemours has also reached a resolution with the West Virginia Rivers Coalition for less than $1 million to resolve its litigation that was commenced in 2024 under the Clean Water Act alleging exceedances of certain permitted discharge limits at the Company's Washington Works facility.About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the expected performance and impact of the cost-sharing arrangements by and between Chemours, Corteva and DuPont related to future eligible PFAS liabilities. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome of the final court approval process for the Consent Decree, including any appeals, the outcome of any pending or future litigation related to PFAS or PFOA, including personal injury claims and natural resource damages claims, the extent and cost of ongoing remediation obligations and potential future remediation obligations, including performance of injunctive actions and mitigation projects under the Consent Decree, changes in laws and regulations applicable to PFAS chemicals, the performance by each of the parties of their respective obligations under the cost-sharing arrangement, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, Chemours' ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of the Company's products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for the Company's segments individually and the Company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, the Company's ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, the Company's ability to make acquisitions, integrate acquired businesses or assets into the Company's operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond the Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect the Company's business and operations and may or may continue to hinder the Company's ability to provide goods and services to customers, cause disruptions in the Company's supply chains such as through strikes, labor disruptions or other events, adversely affect the Company's business partners, significantly reduce the demand for the Company's products, adversely affect the health and welfare of the Company's personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that the Company is unable to identify at this time or that the Company does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025.CONTACTS:INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
investor@chemours.comNEWS MEDIA 
Cassie Olszewski
Media Relations & Reputation Leader 
+1.302.219.7140
media@chemours.com View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-reaches-agreement-with-us-epa-to-resolve-claims-relating-to-pfas-302809444.htmlSOURCE The Chemours Company Original: Chemours Reaches Agreement with U.S. EPA to Resolve Claims Relating to PFAS

New Industry Study, Identifies Path to Cut Cumulative Automotive Refrigerant Emissions Across Europe by ˜50% Between 2030-2050May 13, 2026 6:30 AM
PR Newswire (US) New cross-value-chain research outlines practical pathways to faster emissions reductions, lowering the risk of expensive AC repairs at low cost to consumersWILMINGTON, Del., May 13, 2026 /PRNewswire/ -- A new industry study released today and developed by a technical working group co-led by The Chemours Company (Chemours) (NYSE: CC) and Solstice Advanced Materials Inc. (Nasdaq: SOLS), finds that refrigerant emissions from automotive air conditioning systems in Europe could be reduced by up to 60%+ annually by 2050, with an average of half of cumulative emissions avoided between 2030 and 2050, through coordinated measures implemented across the full automotive value chain.The comprehensive research, conducted by a technical working group and informed by stakeholders involving the whole vehicle lifecycle, including leading automotive manufacturers, suppliers, and refrigerant experts, shows that significant reductions can be achieved. For the European market, the study provides detailed lifecycle-based assessments of refrigerant emissions.The findings highlight the critical role of collaborative industry action and circular economy solutions, including reclamation and recycling, in accelerating Europe's climate and sustainability goals.Key Findings:60%+ reduction in annual refrigerant emissions by 2050 compared with current baseline projections˜ 50% cumulative emissions reduction between 2030 and 2050, supporting long term sustainability goals.Cost-neutral outcomes for consumers, as investments are offset by longer component lifetimes and avoided repair costsComparable effectiveness across internal combustion, hybrid, and battery electric vehicles, underscoring system relevance during the EV transition"This analysis shows that a large share of automotive refrigerant emissions can potentially be avoided using technologies and practices that already exist across today's value chain," said Joseph Martinko, President, Thermal & Specialized Solutions at Chemours. "The data reinforces the importance of lifecycle-based policy approaches that reduce emissions while preserving vehicle performance, affordability, serviceability and supporting the circularity of refrigerants."The study's recommendations are ready for rapid adoption across both conventional combustion engine and electric vehicles, supporting the shift toward a circular economy including end-of-life management through reclamation and recycling programs. These actions are underpinned by broad collaboration across the automotive value chain, paving the way for measurable progress in environmental sustainability and industry best practices. Read the full study here.About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, key findings from research activities related to refrigerant emissions from automotive air conditioning systems, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including research conclusions from third party studies, general economic conditions, geopolitical conditions and global health events, and changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.  CONTACTS:Investor RelationsMediaBrandon OntjesVP, Head of Strategy & Investor RelationsCassie OlszewskiMedia Relations & Reputation Leader+1.302.773.3300+1.302.219.7140investor@chemours.com media@chemours.comLogo - https://mma.prnewswire.com/media/237460/The_Chemours_Company_Logo.jpg View original content:https://www.prnewswire.com/news-releases/new-industry-study-identifies-path-to-cut-cumulative-automotive-refrigerant-emissions-across-europe-by-50-between-2030-2050-302770469.html Original: New Industry Study, Identifies Path to Cut Cumulative Automotive Refrigerant Emissions Across Europe by ˜50% Between 2030-2050

Chemours Announces Second Quarter DividendMay 5, 2026 10:07 PM
PR Newswire (US) WILMINGTON, Del., May 5, 2026 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC) today announced that the Board of Directors of Chemours declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the second quarter of 2026. The dividend will be paid on June 16, 2026, to stockholders of record as of the close of business on May 17, 2026. About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. CONTACTS:INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.comNEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com   View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-second-quarter-dividend-302763517.htmlSOURCE The Chemours Company Original: Chemours Announces Second Quarter Dividend

The Chemours Company Reports First Quarter ResultsMay 5, 2026 4:58 PM
PR Newswire (US) WILMINGTON, Del., May 5, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the first quarter 2026.Key First Quarter 2026 Results & Recent Highlights1Net Sales of $1.4 billion, slightly up compared to the corresponding prior-year quarter, with TSS reporting record first quarter results, with continued double-digit year-over-year sales growth in Opteon™ RefrigerantsNet Loss attributable to Chemours of $29 million, or $0.19 per diluted share, compared with Net Loss attributable to Chemours of $5 million, or $0.03 per diluted share, in the corresponding prior-year quarterAdjusted Net Income2 of $8 million, or $0.05 per diluted share, compared to Adjusted Net Income of $19 million, or $0.13 per diluted share, in the corresponding prior-year quarterAdjusted EBITDA2,3 of $169 million compared to $166 million in the corresponding prior-year quarterAnnounced a global TiO2 price increase effective April 1, 2026, as a continuation of our December price actions; achieved a sequential TiO2 price increase of 3% in Net SalesReceived ~$287 million initial net proceeds from the sale of the Kuan Yin site, positioning the Company to paydown €140 million of outstanding debt"Chemours exceeded overall expectations in the first quarter, achieving strong outcomes from both our TSS and TT businesses, paired with the more recent receipt of cash through the completion of a substantial portion of our Kuan Yin property sales enabling us to reduce our debt," stated Denise Dignam, Chemours President and CEO. "These achievements demonstrate our dedication to our Pathway to Thrive strategy and highlight the importance we place on effective execution. While the wider economic landscape remains uncertain, Chemours continues to drive full-year growth while remaining steadfast in prioritizing flexible commercial and operational strategies to ensure Chemours is able to capitalize on opportunities in our key markets." Total Chemours
Q1 2026Q1 2025Y-o-Y % ?Q4 2025Q-o-Q % ?Net Sales (millions)$1,381$1,3681 %$1,3294 %Net Loss (millions)($29)($5)(480 %)($47)38 %Loss Per Share4($0.19)($0.03)(533 %)($0.31)39 %Adjusted Net Income$8$19(58 %)$714 %Adjusted EPS$0.05$0.13(62 %)$0.050 %Adjusted EBITDA (millions)$169$1662 %$12832 %First quarter 2026 Net Sales were $1.4 billion, an increase of 1% compared to the prior-year quarter. Reported Net Sales were primarily driven by a 2% increase in price and a 3% increase in currency, partially offset by a 4% decrease in volumes. The overall increase in price was driven by automotive Freon™ pricing for TSS in North America, partially offset by TT and APM. The decrease in volume was primarily driven by constraints in production due to an operational outage in APM and weaker cyclical end markets impacting both TT and APM, partially offset by continued strength in TSS volume tied to increased Opteon™ Refrigerants adoption and Freon™ sales. First quarter 2026 Net Loss attributable to Chemours was $29 million, or $0.19 per diluted share, compared to Net Loss attributable to Chemours of $5 million, or $0.03 per diluted share in the prior-year quarter. The larger first quarter Net Loss attributable to Chemours was driven by increased financing costs associated with a recent debt offering and higher Selling, General and Administrative costs. Adjusted EBITDA for the first quarter of 2026 was $169 million, compared to $166 million in the prior-year quarter with the referenced higher pricing, currency and other income more than offsetting overall higher costs paired with lower sales volumes in APM and TT.Thermal & Specialized Solutions
Q1 2026Q1 2025Y-o-Y % ?Q4 2025Q-o-Q % ?Net Sales (millions)$568$46622 %$44428 %Opteon™ Refrigerants$313$27912 %$24329 %Freon™ Refrigerants$162$9767 %$11343 %Foam, Propellants & Other (FP&O)$93$903 %$877 %Adjusted EBITDA (millions)$190$14135 %$12848 %Adjusted EBITDA Margin33 %30 %3 ppts29 %4 pptsFor the first quarter of 2026, TSS segment results reflected both record sales, inclusive of a 12% year-over-year growth in Opteon™ Refrigerants, and Adjusted EBITDA.TSS segment first quarter 2026 Net Sales were $568 million, an increase of 22% versus the prior-year quarter, driven by an 11% increase in price and a 9% increase in volume, with a 2% currency tailwind. Increased pricing was primarily driven by automotive Freon™ Refrigerant sales in North America. Volume growth was driven by the continued transition to Opteon™ Refrigerants as well as automotive Freon™ Refrigerant sales in North America.Adjusted EBITDA for the quarter increased 35% to $190 million, while Adjusted EBITDA Margin increased three points to 33%. The increase in Adjusted EBITDA was driven by higher pricing associated with the referenced automotive Freon™ sales and a transition to a more favorable product mix in Opteon™ Refrigerant blends, partially offset by higher input costs associated with R32, a key component of our stationary Opteon™ Refrigerant blends, in the quarter.Sequentially, Net Sales increased 28%, driven by a 22% seasonal volume increase supported by a 6% pricing increase. Volumes followed seasonal patterns, increasing across all refrigerants.  Titanium Technologies
Q1 2026Q1 2025Y-o-Y % ?Q4 2025Q-o-Q % ?Net Sales (millions)$559$597(6 %)$561(0 %)  TiO2 Pigment$541$575(6 %)$5341 %  Minerals$18$22(18 %)$27(33 %)Adjusted EBITDA (millions)$18$50(64 %)$23(22 %)Adjusted EBITDA Margin3 %8 %(5) ppts4 %(1) pptsTT segment first quarter 2026 Net Sales were $559 million, a 6% decrease compared to the prior-year quarter. This decrease was the result of a 7% decline in volumes globally, with favorable currency of 3% more than offsetting lower pricing of 2%. The decrease in volumes was driven by lower TiO2 sales concentrated in North America and certain non-western markets, which also negatively impacted product mix.TT segment first quarter 2026 Adjusted EBITDA decreased 64% to $18 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased five percentage points to 3%. The decline in Adjusted EBITDA was primarily driven by the decline in sales as well as an unfavorable ore mix with Q1 production paired with decisions to adjust TT's mining footprint.Sequentially, TT segment first quarter 2026 Net Sales were approximately flat, with a 3% increase in price, reflective of pricing actions announced in the fourth quarter of 2025, offset by a 3% decrease in volume.Advanced Performance Materials
Q1 2026Q1 2025Y-o-Y % ?Q4 2025Q-o-Q % ? Net Sales (millions)$243$294(17 %)$312(22 %)Advanced Materials$143$178(20 %)$172(17 %)Performance Solutions$100$116(14 %)$141(29 %)Adjusted EBITDA (millions)$5$32(84 %)$12(58 %)Adjusted EBITDA Margin2 %11 %(9) ppt4 %(2) pptsAPM segment first quarter 2026 Net Sales were $243 million, a 17% decrease compared to the prior-year quarter. This decrease was primarily driven by a 19% decrease in volume with favorable currency of 3% further offsetting a 1% decrease in price. The volume decline was primarily driven by sales constraints due to the Washington Works plant outage in Q1 and recent closure of APM's Advanced Materials SPS Capstone™ line, completed in the third quarter of 2025.APM segment first quarter 2026 Adjusted EBITDA decreased 84% to $5 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased nine percentage points to 2%. The decrease in Adjusted EBITDA was primarily driven by the referenced lower sales volumes and related additional costs from the outage which combined for approximately $25 million for the quarter.Sequentially, APM segment first quarter 2026 Net Sales were down approximately 22%, driven by a 22% decrease in volumes, related to decreased volumes across both Performance Solutions and Advanced Materials. The decline in volumes was due to the referenced first quarter Washington Works outage as well as contractual sales timing.Other Non-Reportable SegmentThe Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the first quarter 2026 of $11 million and $3 million, respectively.Corporate ExpensesCorporate Expenses were $47 million in the first quarter of 2026, a decrease of approximately $10 million compared to the prior-year quarter. This was primarily due to lower costs associated with legacy litigation activities.Liquidity and Capital AllocationAs of March 31, 2026, consolidated gross debt was $4.2 billion5. Debt, net of $563 million in unrestricted cash and cash equivalents, was $3.6 billion, resulting in a net leverage ratio of approximately 4.9x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.5 billion, comprised of $563 million in unrestricted6 cash and cash equivalents and $953 million of revolving credit facility capacity, net of outstanding letters of credit.In April 2026, the Company completed the sale of nine of the ten parcels of land at the Company's Kuan Yin site which are classified as held-for-sale and received net cash proceeds of approximately $287 million. The sale of the tenth parcel of land is expected to be completed by the end of 2026 for a remaining gross purchase price of approximately $55 million. Using part of the initial cash proceeds received, as well as cash on hand, in April 2026, the Company paid down €140 million of the outstanding tranche B-3 Euro Term loans due August 2028. The Company expects further debt repayments in 2026.Operating cash usage for the first quarter of 2026 was $44 million, compared to a usage of $112 million in the prior-year quarter highlighting improvements in net working capital performance.Capital expenditures for the first quarter of 2026 amounted to $49 million, a decrease in spend compared to $84 million in the prior-year quarter, driven by lower capital expenditures in TSS.Free Cash Flows for the first quarter of 2026 reflected a usage of $93 million, compared to a usage of $196 million in the first quarter of 2025.Second Quarter 2026 OutlookIn the second quarter, the Company anticipates consolidated Net Sales to increase in the range of 15% to 20%, sequentially, driven by favorable seasonal trends, with consolidated Adjusted EBITDA expected to range between $220 million and $250 million. Corporate Expenses are expected to approximate $45 million to $50 million. The Company also anticipates capital expenditures to approximate $50 million, with Free Cash Flows of at least $100 million.TSS projects Net Sales will sequentially increase in the low-to-mid teens percentage range, driven by seasonality in connection with the 2026 cooling season in the northern hemisphere with strength in both Freon™ and Opteon™ Refrigerants. Adjusted EBITDA is expected to be between $210 million and $225 million.TT expects an overall sequential Net Sales increase in the mid-to high teens percentage range, driven by seasonal volume strength and a favorable mix for TiO2 pigment, supported by recent pricing actions, paired with increased minerals sales. Adjusted EBITDA is expected to range between $40 million and $50 million.APM expects a sequential Net Sales increase in the low-to-high thirties percentage range, driven by a return to normal operating levels at the Washington Works facility while reflecting some limited residual impacts from the outage. Adjusted EBITDA for APM is expected to be between $12 million and $18 million.Full Year 2026 OutlookThe Company continues to expect 2026 Net Sales to grow in the range of 3% to 5% over 2025, with Adjusted EBITDA between $800 million and $900 million. This outlook is supported by higher TSS and APM Performance Solutions demand, anticipated TT pricing momentum, and ongoing cost improvements in each business. Capital expenditures are anticipated to be between $275 million and $325 million, with overall Free Cash Flow Conversion above 20%, due to increased earnings and improvements in working capital throughout the year. This revised estimate now reflects the approximate $30 million estimated full year income tax cash outflow related to the expected proceeds to be distributed on the sale of land at the former Kuan Yin TiO2 site. As an update to previous expectations, the Company anticipates that these cash flow dynamics will produce a net leverage ratio of less than 3.8x by the end of 2026.Conference CallAs previously announced, Chemours will hold a conference call and webcast on May 6, 2026, at 8:00 AM Eastern Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.About The Chemours CompanyThe Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.Non-GAAP Financial MeasuresWe prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.Forward-Looking StatementsThis press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2026, the full year 2026 and the Company's corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, global conflicts, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.CONTACTS:INVESTORS 
Brandon Ontjes 
Vice President, Head of Strategy & Investor Relations 
+1.302.773.3309
investor@chemours.com   NEWS MEDIA 
Cassie Olszewski
Media Relations & Reputation Leader 
+1.302.219.7140
media@chemours.com




1Certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Annual Report on Form 10-K for the year ended December 31, 2025.2Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".3Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.4On a diluted earnings per share basis.5This amount does not reflect the €140 million used to reduce outstanding debt, which occurred in April of 2026.6Restricted cash approximated $53 million of the end of the first quarter of 2026, reflecting primarily escrow payments Chemours has made related to the MOU agreement with DuPont, Corteva and EID as further described in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The Chemours CompanyConsolidated Statements of Operations (Unaudited)1(Dollars in millions, except per share amounts)


Three Months Ended March 31,


2026

2025
Net sales
$1,381

$1,368
Cost of goods sold

1,169


1,132
Gross profit

212


236
Selling, general, and administrative expense

147


123
Research and development expense

26


27
Restructuring, asset-related, and other charges

13


33
Total other operating expenses

186


183
Equity in earnings of affiliates

8


8
Interest expense, net

(69)


(66)
Loss on extinguishment of debt

(9)


—
Other income, net

22


5
Loss before income taxes

(22)


—
Provision for income taxes

7


5
Net loss

(29)


(5)
Net loss attributable to Chemours
$(29)

$(5)
Per share data





Basic (loss) earnings per share of common stock
$(0.19)

$(0.03)
Diluted (loss) earnings per share of common stock     

(0.19)


(0.03)
 The Chemours CompanyConsolidated Balance Sheets (Unaudited)1(Dollars in millions, except per share amounts)








March 31, 2026

December 31, 2025
Assets





Current assets:





Cash and cash equivalents
$563

$670
Restricted cash and restricted cash equivalents

—


2
Accounts and notes receivable, net

759


679
Inventories

1,536


1,569
Prepaid expenses and other

69


80
Assets held for sale

1


1
Total current assets

2,928


3,001
Property, plant, and equipment

9,925


9,920
Less: Accumulated depreciation

(6,885)


(6,842)
Property, plant, and equipment, net

3,040


3,078
Operating lease right-of-use assets

274


271
Goodwill

46


46
Other intangible assets, net

2


2
Investments in affiliates

166


160
Assets held for sale, non-current

21


21
Restricted cash and restricted cash equivalents

52


52
Other assets

738


751
Total assets
$7,267

$7,382
Liabilities





Current liabilities:





Accounts payable
$891

$954
Compensation and other employee-related cost

122


96
Short-term and current maturities of long-term debt

37


42
Current environmental remediation

97


88
Other accrued liabilities

462


506
Total current liabilities

1,609


1,686
Long-term debt, net

4,100


4,099
Operating lease liabilities

192


191
Long-term environmental remediation

520


530
Deferred income taxes

40


37
Other liabilities

590


588
Total liabilities

7,051


7,131
Commitments and contingent liabilities





Equity





Common stock (par value $0.01 per share; 810,000,000 shares authorized;
199,180,562 shares issued and 150,355,228 shares outstanding at March 31,
2026; 198,720,786 shares issued and 149,893,993 shares outstanding at
December 31, 2025)

2


2
Treasury stock, at cost (48,825,334 shares at March 31, 2026 and 48,826,793 at
December 31, 2025)

(1,802)


(1,802)
Additional paid-in capital

1,081


1,074
Retained earnings

1,178


1,220
Accumulated other comprehensive loss

(244)


(244)
Total Chemours stockholders' equity

215


250
Non-controlling interests

1


1
Total equity

216


251
Total liabilities and equity
$7,267

$7,382
 The Chemours CompanyConsolidated Statements of Cash Flows (Unaudited)1(Dollars in millions)


Three Months Ended March 31,


2026

2025
Cash flows from operating activities





Net loss
$(29)

$(5)
Adjustments to reconcile net income to cash used for operating activities:





Depreciation and amortization

79


88
Loss (gain) on sales of assets and businesses

—


(1)
Equity in earnings of affiliates, net

(6)


(7)
Loss on extinguishment of debt

9


—
Amortization of debt issuance costs and issue discounts

3


3
Deferred tax benefit

(11)


(14)
Asset-related charges

1


1
Stock-based compensation expense

7


5
Net periodic pension cost (income)

—


—
Defined benefit plan contributions

(1)


(4)
Other operating charges and credits, net

(14)


37
Decrease (increase) in operating assets:





Accounts and notes receivable, net

(77)


(111)
Inventories and other current operating assets

32


(51)
Other non-current operating assets

17


48
(Decrease) increase in operating liabilities:





Accounts payable

(58)


(105)
Other current operating liabilities

12


(5)
Other non-current operating liabilities

(8)


9
Cash used for operating activities

(44)


(112)
Cash flows from investing activities





Purchases of property, plant, and equipment

(49)


(84)
Proceeds from life insurance policies

1


—
Proceeds from sales of assets and businesses

7


—
Foreign exchange contract settlements, net

(3)


(2)
Cash used for investing activities

(44)


(86)
Cash flows from financing activities





Proceeds from issuance of debt

700


—
Debt repayments

(689)


(8)
Payments on finance leases

(3)


(3)
Payments of debt issuance cost

(10)


—
Proceeds from supplier financing program

16


27
Payments to supplier financing program

(14)


(35)
Proceeds from exercised stock options, net

2


—
Payments related to tax withholdings on vested stock awards

(2)


(1)
Payments of dividends to the Company's common shareholders

(13)


(37)
Debt extinguishment payments

(6)


—
Cash used for financing activities

(19)


(57)
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash
equivalents

(2)


6
Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents

(109)


(249)
Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,

724


763
Cash, cash equivalents, restricted cash and restricted cash equivalents at March 31,
$615

$514







Supplemental cash flows information





Non-cash investing and financing activities:





Purchases of property, plant, and equipment included in accounts payable
$27

$26
 The Chemours CompanySegment Financial and Operating Data (Unaudited)(Dollars in millions)
Segment Net Sales1











Three Months











Ended

Sequential

Three Months Ended March 31,

Increase /

December 31,

Increase /

2026

2025

(Decrease)

2025

(Decrease)
Thermal & Specialized Solutions$
568

$
466

$
102

$
444

$
124
Titanium Technologies

559



597



(38)



561



(2)
Advanced Performance
Materials

243



294



(51)



312



(69)
Other Non-Reportable Segment

11



11



0



12



(1)
Total Net Sales$
1,381

$
1,368

$
13

$
1,329

$
52

























Segment Adjusted EBITDA1








Three Months

















Ended

Sequential

Three Months Ended March 31,

Increase /

December 31,

Increase /

2026

2025

(Decrease)

2025

(Decrease)
Thermal & Specialized Solutions$
190

$
141

$
49

$
128

$
62
Titanium Technologies$
18

$
50

$
(32)

$
23

$
(5)
Advanced Performance
Materials$
5

$
32

$
(27)

$
12

$
(7)
Other Non-Reportable Segment$
3

$
1

$
2

$
1

$
2

























Quarterly Change in Net Sales from the three months ended March 31, 2025
















March 31, 2026

Percentage Change
vs.
Percentage Change Due To

Net Sales

March 31, 2025
Price
Volume
Currency
Portfolio
Total Company$
1,381


1%
2%
(4)%
3%
—%














Thermal & Specialized Solutions$
568


22%
11%
9%
2%
—%Titanium Technologies

559


(6)%
(2)%
(7)%
3%
—%Advanced Performance
Materials

243


(17)%
(1)%
(19)%
3%
—%Other Non-Reportable Segment

11


—%
(2)%
2%
—%
—%




















Quarterly Change in Net Sales from the three months ended December 31, 2025
















March 31, 2026

Percentage Change
vs.
Percentage Change Due To

Net Sales

December 31, 2025
Price
Volume
Currency
Portfolio
Total Company$
1,381


4%
3%
1%
—%
—%














Thermal & Specialized Solutions$
568


28%
6%
22%
—%
—%Titanium Technologies

559


—%
3%
(3)%
—%
—%Advanced Performance
Materials

243


(22)%
—%
(22)%
—%
—%Other Non-Reportable Segment

11


(2)%
5%
(7)%
—%
—% The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
 GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation1Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

Three Months Ended

Twelve Months Ended


March 31,

December 31,

March 31,


2026

2025

2025

2026

2025
(Loss) income before income taxes
$
(22)

$
—

$
(67)

$
(299)

$
38
Net (loss) income attributable to Chemours
$
(29)

$
(5)

$
(47)

$
(409)

$
12
Non-operating pension and other post-retirement
employee benefit (income) cost


(2)



(2)



(3)



(11)



(5)
Exchange (gains) losses, net


(1)



3



4



8



13
Restructuring, asset-related, and other charges (1)


13



32



4



39



85
Goodwill impairment charge (2)


—



—



—



—



56
Loss (gain) on extinguishment of debt (3)


9



—



5



14



1
Gain on sales of assets and businesses, net (4)


—



(1)



—



(7)



(1)
Transaction costs (5)


2



—



4



8



2
Qualified spend recovery (6)


(5)



(9)



(7)



(38)



(28)
Litigation-related charges (7)


20



—



19



340



2
Environmental charges (8)


7



—



20



100



15
Adjustments made to income taxes (9)


1



1



19



181



9
(Benefit from) provision for income taxes relating to
reconciling items (10)


(7)



—



(11)



(92)



(9)
Adjusted Net Income


8



19



7



133



152
Net income attributable to non-controlling interests


—



—



(1)



—



—
Interest expense, net


69



66



68



272



267
Depreciation and amortization (11)


79



77



81



319



299
All remaining provision for income taxes (10)


13



4



(27)



22



25
Adjusted EBITDA
$
169

$
166

$
128

$
746

$
743





















Total debt principal












$
4,183

$
4,147
Less: Cash and cash equivalents














(563)



(464)
Total debt principal, net












$
3,620

$
3,683





















Net Leverage Ratio (calculated using GAAP
earnings) (12)













(12.1)x


96.9x
Net Leverage Ratio (calculated using Non-GAAP
earnings) (12)













4.9x


5x
GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
 GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)1(1)For the twelve months ended March 31, 2026, restructuring, asset-related and other charges primarily includes employee separation charges related to the 2026 Restructuring Program as well as charges related to our decision to exit our SPS CapstoneTM business. For the twelve months ended March 31, 2025, restructuring, asset-related and other charges primarily include charges related to our decision to exit our SPS CapstoneTM business and the 2024 Restructuring Program. See "Note 4 –Restructuring, Asset-Related and Other Charges" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.(2)For the twelve months ended March 31, 2025, this represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025.(3)For the twelve months ended March 31, 2026, loss on extinguishments of debt reflects costs associated with early redemption of the 2027 senior unsecured notes and partial early redemption of our 2028 senior unsecured notes during the first quarter of 2026. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.(4)For the twelve months ended March 31, 2026, gain on sales of assets and businesses, net includes a gain on sale of $7 million related to certain parcels of land at the Company's manufacturing site in Kuan Yin, Taiwan.(5)For the twelve months ended March 31, 2025, transaction costs include $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 15 - Debt" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details. (6)Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.(7)Litigation-related charges pertain to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended March 31, 2026, litigation-related charges primarily includes $266 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $12 million in third-party legal fees directly related to the New Jersey Settlement agreement, $14 million related to the Company's portion of Chemours, DuPont, Corteva, EID's settlement agreement to resolve the Hoosick Falls class action lawsuit, $15 million related to alleged violations and discharge exceedances and $18 million related to reserves for asbestos and production liability matters. For the twelve months ended March 31, 2025, litigation-related charges include a $29 million accrual associated with the Ohio MDL and $27 million of benefits from insurance recoveries. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.(8)Environmental charges pertain to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended March 31, 2026, environmental charges primarily include changes to remediation reserves at the four sites covered by the New Jersey settlement agreement. See "Note 17 – Commitments and Contingent Liabilities" to the Interim Consolidated Financial Statements in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 for further details.(9)Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.(10)The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.(11)For the twelve months ended March 31, 2026 and March 31, 2025, accelerated depreciation charges of $12 million and $11 million, respectively, incurred as part of our decision to exit our SPS CapstoneTM business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.(12)Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation1Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which include unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.

Three Months Ended

March 31,
December 31,

2026
2025
2025Numerator:






Net (loss) income attributable to Chemours
$(29)
$(5)
$(47)Adjusted Net Income

8

19

7Denominator:





Weighted-average number of common shares outstanding -
basic

150,767,077

149,918,386

150,464,150Dilutive effect of the Company's employee compensation plans
(1)

819,728

491,194

398,511Weighted-average number of common shares outstanding -
diluted (1)

151,586,805

150,409,579

150,862,661






Basic (loss) earnings per share of common stock (2)
$(0.19)
$(0.03)
$(0.31)Diluted (loss) earnings per share of common stock (1) (2)

(0.19)

(0.03)

(0.31)Adjusted basic earnings per share of common stock (2)

0.05

0.13

0.05Adjusted diluted earnings per share of common stock (1) (2)

0.05

0.13

0.05

(1)In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended March 31, 2026, three months ended March 31, 2025 and the three months ended December 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended March 31, 2026, three months ended March 31, 2025 and the three months ended December 31, 2025 as Adjusted Net Income was in a net income position.(2)Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion ReconciliationFree Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

Three Months Ended


March 31,

December 31,


2026

2025

2025
Cash flows (used for) provided by operating activities
$
(44)

$
(112)

$
137
Less: Purchases of property, plant, and equipment


(49)



(84)



(45)
Free Cash Flows
$
(93)

$
(196)

$
92
Adjusted EBITDA


169



166



128
Free Cash Flow Conversion


(55)%


(118)%


72%2026 Estimated GAAP Cash Flow Provided by Operating Activities to Estimated Free Cash Flows and Estimated Free Cash Flow Conversion Reconciliation (1)Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

Estimated


Year Ended December 31, 2026


Low

High
Cash flows provided by (used for) operating activities
$
445

$
565
Less: Purchases of property, plant, and equipment


(275)



(325)
Free Cash Flows
$
170

$
240
Adjusted EBITDA


800



900
Free Cash Flow Conversion


21%


27%

(1)Cash flows provided by operating activities is inclusive of the anticipated $30 million cash taxes associated with the sale of the Kuan Yin site.The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)2026 Estimated GAAP Net Income Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)

(Estimated)

Year Ending December 31, 2026

Low

HighNet income attributable to Chemours
$165

$225Restructuring, transaction, and other costs, net (2)

(35)


(45)Adjusted Net Income

130


180Interest expense, net

275


285Depreciation and amortization

315


325All remaining provision for income taxes

80


110Adjusted EBITDA
$800

$900

(1)The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.(2)Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.  View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-reports-first-quarter-results-302763268.htmlSOURCE The Chemours Company Original: The Chemours Company Reports First Quarter Results

Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference CallApril 21, 2026 4:30 PM
PR Newswire (US)

WILMINGTON, Del., April 21, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.Replay: A webcast replay will be available at investors.chemours.com.About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. CONTACTS:INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.comNEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com  





View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-dates-for-first-quarter-2026-earnings-release-and-webcast-conference-call-302749283.htmlSOURCE The Chemours Company

Original: Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference Call

dumping $CC

The Chemours Company Announces Completion of Private Offering of $700,000,000 Aggregate Principal Amount of 7.875% Senior Unsecured Notes Due 2034March 12, 2026 5:00 PM
PR Newswire (US)

WILMINGTON, Del., March 12, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC) today announced it completed its previously announced private offering of $700,000,000 in aggregate principal amount of 7.875% senior unsecured notes due 2034 (the "Notes") that was exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). The Notes are Chemours' senior unsecured obligations and are guaranteed by one of its subsidiaries.Chemours used the net proceeds from the offering, together with cash on hand, to fund the redemption of $188,000,000 aggregate principal amount of its 5.750% senior notes due 2028 for an aggregate redemption price of approximately $189,800,000, plus accrued and unpaid interest thereon. The remaining net proceeds from the offering are expected to be used to fund the redemption of the outstanding 5.375% senior notes due 2027 for an aggregate redemption price of approximately $500,300,000 in (assuming a treasury rate of 3.56%), plus accrued and unpaid interest to, but excluding, the date of redemption.The Notes and the related guarantee have not been, and will not be, registered under the Securities Act or any state securities laws, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. The Notes were offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and to non-U.S. persons in accordance with Regulation S under the Securities Act.This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not an offer to purchase or the solicitation of an offer to sell any of the existing 2027 or 2028 notes. The statements in this press release with respect to the redemption of the existing 2027 or 2028 notes do not constitute a notice of redemption under the indenture governing the existing 2027 or 2028 notes, as applicable. Any such notice has or will be sent to holders of existing 2027 and 2028 notes only in accordance with the provisions of each such indenture, as applicable.About The Chemours CompanyThe Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.Forward-Looking Statements This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements address, among other things, Chemours' intended use of the net proceeds therefrom, including the expectation to redeem all of the outstanding existing 2027 notes. Forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the redemption of the existing 2027 notes and other risks, uncertainties and other factors discussed in Chemours' filings with the U.S. Securities and Exchange Commission, including in Chemours' Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.CONTACTS: INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3309
investor@chemours.comNEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-announces-completion-of-private-offering-of-700-000-000-aggregate-principal-amount-of-7-875-senior-unsecured-notes-due-2034--302712827.htmlSOURCE The Chemours Company

Original: The Chemours Company Announces Completion of Private Offering of $700,000,000 Aggregate Principal Amount of 7.875% Senior Unsecured Notes Due 2034

The Chemours Company Announces Upsizing and Pricing of Private Offering of $700,000,000 of 7.875% Senior Notes Due 2034February 26, 2026 4:39 PM
PR Newswire (US)

WILMINGTON, Del., Feb. 26, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC) today announced the pricing of its previously announced private offering of $700,000,000 aggregate principal amount of new 7.875% senior notes due 2034 (the "Notes"). The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of Notes. The Notes will bear interest at 7.875% per annum and mature on March 15, 2034. Interest on the Notes will be payable semi-annually on March 15 and September 15 of each year, beginning on September 15, 2026. The Notes will be senior unsecured obligations of Chemours and will be guaranteed by certain of its subsidiaries. The offering is expected to close on March 12, 2026, subject to customary closing conditions.







Chemours intends to use the net proceeds from the offering to fund the redemption of its outstanding 5.375% senior notes due 2027 and the partial redemption of its outstanding 5.750% senior notes due 2028.The Notes and related guarantees were offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), or outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes and related guarantees.The Notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.About The Chemours CompanyThe Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries.Forward-Looking StatementsThis press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the closing of the offering of Notes and Chemours' intended use of the net proceeds therefrom, which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the ability of Chemours to satisfy the conditions to closing the offering and general market conditions which may impact the closing of the offering. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside Chemours' control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect Chemours' business and operations and may or may continue to hinder Chemours' ability to provide goods and services to customers, cause disruptions in Chemours' supply chains such as through strikes, labor disruptions or other events, adversely affect Chemours'  business partners, significantly reduce the demand for Chemours' products, adversely affect the health and welfare of Chemours' personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include whether the offering of Notes is completed and other risks, uncertainties and other factors discussed in Chemours' filings with the U.S. Securities and Exchange Commission, including in Chemours' Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.CONTACTS: INVESTORS
Brandon Ontjes
Vice President, Investor Relations
+1.302.773.3309
investor@chemours.comNEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-announces-upsizing-and-pricing-of-private-offering-of-700-000-000-of-7-875-senior-notes-due-2034--302699031.htmlSOURCE The Chemours Company

Original: The Chemours Company Announces Upsizing and Pricing of Private Offering of $700,000,000 of 7.875% Senior Notes Due 2034

Following Successful Fluid Qualification Chemours & 2CRSi Join Forces to Accelerate Deployment of Two-Phase Liquid Cooling for High-Density Servers & IT EquipmentFebruary 24, 2026 4:30 PM
PR Newswire (US)

Successful qualification of Opteon™ fluid in 2CRSi server sparks broader collaboration to drive innovation in new and existing technologies across respective portfoliosWILMINGTON, Del. and STRASBOURG, France, Feb. 24, 2026 /PRNewswire/ -- The Chemours Company (NYSE: CC), a global chemistry company, and 2CRSi (ISIN code: FR0013341781), a pioneer in high-performance, eco-responsible server technology, today announced a Joint Development Agreement (JDA)1 following the successful qualification of Chemours' Opteon™ two-phase immersion cooling fluid in current-generation 2CRSi servers. This milestone sets the stage for accelerating the development and deployment of advanced two-phase cooling technologies—including direct-to-chip and immersion systems—for high-density IT infrastructure, supporting AI and next-generation chips.







Building on this qualification success, the partnership will combine Chemours' advanced thermal management expertise and 2CRSi's server design leadership to deliver substantial end-user and environmental benefits, meeting near- and long-term data center and IT cooling demands."At Chemours, we firmly believe two-phase liquid cooling is the key to unlocking the next generation of high-performance computing, and we're thrilled to partner with 2CRSi to meet the unprecedented demands of AI and advanced IT workloads—while dramatically reducing energy and water consumption," said Nathan Blom, Vice President of Liquid Cooling at Chemours. "This partnership will not only deliver innovative cooling solutions; it will empower customers to future-proof their infrastructure and accelerate the transition to more efficient, resilient digital ecosystems."Chemours' Opteon™ two-phase liquid cooling solutions can deliver up to a 90% reduction in data center cooling energy compared to traditional air cooling, a power usage effectiveness (PUE) approaching 1, dramatic reductions in water consumption, and a circular solution through fluid recovery and reuse. Additionally, accelerated life cycle testing confirms compatibility with industry-standard IT components.These environmental and operational advantages align with 2CRSi's commitment to decarbonizing digital infrastructure. Leveraging Chemours' next-generation fluids, 2CRSi has successfully commercialized ultra-high-density servers—such as the Atlas 1.8GG 2PIC model—housing 8 NVIDIA H200 GPUs in a 1U format, a technical achievement enabled by two-phase cooling."2CRSi has always been a pioneer in server cooling. As the industry embraces liquid cooling, we are proud to collaborate with Chemours to deliver some of the most efficient and innovative solutions available today," said Alain Wilmouth, CEO at 2CRSi. "This partnership reflects a shared vision to address the surging energy demands of AI and GPU-accelerated computing. Together, Chemours and 2CRSi are paving the way for compact, energy-efficient edge data centers capable of powering low-latency applications such as autonomous vehicles, 5G/6G networks, and intelligent embedded systems."The companies will focus on pushing technological boundaries to deliver efficient, high-density servers for AI and HPC, targeting advanced formats like 15 kW, 1U servers powered by Nvidia GPUs.About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.About 2CRSi
Founded in 2005 in Strasbourg (France), 2CRSi designs, develops, and manufactures high-performance computer servers and innovative solutions for Artificial Intelligence, high-performance computing, and data storage. Committed to a responsible and sustainable approach, the group operates across multiple continents and delivers energy-efficient technological solutions to sectors including tech, industry, gaming, scientific research, and datacenters.
2CRSi has been listed since June 2018 on the Euronext Paris regulated market (ISIN code: FR0013341781) and transferred to Euronext Growth in November 2022.For more information: www.2crsi.comForward-Looking Statements 
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things,  new product development, expected contributions to advancing the data center energy efficiency, addressing new innovative markets, such as AI, improving sustainability, circularity, decreasing environmental footprint, plans to continue investment in research and development, advancements in liquid cooling technology, partnerships in the liquid cooling and data center industry, and development agreements with partners all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, and changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products or increase raw material, energy or other input costs, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.Chemours ContactsINVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300
investor@chemours.comNEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com 2CRSi Contacts2CRSiJean-Philippe LLOBERADirector Francepress@2crsi.com 03 68 41 10 70Seitosei.ActifinFoucauld CharavayFinancial communicationfoucauld.charavay@seitosei-actifin.com06 37 83 33 19Seitosei.ActifinPress Relationspresse@seitosei-actifin.com06 85 36 85 111 This agreement formalizes an in-depth technological collaboration between the two companies, following several years of successful testing conducted on 2CRSi's Atlantis™ and Octopus™ servers with the Opteon™ 2P50 fluid developed by Chemours.










View original content to download multimedia:https://www.prnewswire.com/news-releases/following-successful-fluid-qualification-chemours--2crsi-join-forces-to-accelerate-deployment-of-two-phase-liquid-cooling-for-high-density-servers--it-equipment-302696261.htmlSOURCE The Chemours Company

Original: Following Successful Fluid Qualification Chemours & 2CRSi Join Forces to Accelerate Deployment of Two-Phase Liquid Cooling for High-Density Servers & IT Equipment

Chemours' Gerardo Familiar Appointed to SEMI North America Advisory BoardFebruary 23, 2026 4:30 PM
PR Newswire (US)

Advanced Performance Materials business president to help guide SEMI's efforts supporting North America's semiconductor innovation and supply chain resilienceWILMINGTON, Del., Feb. 23, 2026 /PRNewswire/ --The Chemours Company (Chemours) (NYSE: CC), a global chemistry company, today announced that Gerardo Familiar, President of the company's APM business, has been appointed to the SEMI North America Advisory Board (NAAB). SEMI is a global industry association serving thousands of member companies across the semiconductor and electronics design and manufacturing supply chain. The SEMI NAAB serves as the principal advocate for member companies throughout North America, providing strategic guidance on programs that advance semiconductor industry growth, supply chain robustness, sustainability, workforce development, and manufacturing excellence."Semiconductors are the backbone of modern technology, and Chemours responsibly delivers essential materials that enable next-generation performance, efficiency, and the reliability needed," said Gerardo Familiar, President of Advanced Performance Materials at Chemours. "I am honored to serve on the SEMI North America Advisory Board at such a pivotal time and look forward to partnering with SEMI and its members to help shape the future of the industry and support the continued growth of the North American semiconductor ecosystem.""We are delighted to see Gerardo join the SEMI North America Advisory Board," said Joe Stockunas, President of SEMI America's. "His deep knowledge of advanced fluoropolymers and leadership across global semiconductor markets make him an ideal advocate for the materials science innovations essential to next-generation electronics."Familiar brings more than 25 years of global experience across business strategy, commercial excellence, marketing, finance, product management, operations and regulatory affairs. As President of APM, he leads a portfolio of critical chemistries, including high-performance fluoropolymers used across semiconductor manufacturing, clean energy, advanced electronics, and other high-technology sectors. His leadership has been central to Chemours' efforts to expand capacity, drive product innovation, and champion responsible manufacturing.Familiar's SEMI NAAB appointment took effect on January 14, 2026, marking the beginning of his three-year term.About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3309
investor@chemours.com NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-gerardo-familiar-appointed-to-semi-north-america-advisory-board-302694919.htmlSOURCE The Chemours Company

Original: Chemours' Gerardo Familiar Appointed to SEMI North America Advisory Board

The Chemours Company Reports Fourth Quarter and Full Year 2025 ResultsFebruary 19, 2026 4:38 PM
PR Newswire (US)

WILMINGTON, Del., Feb. 19, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the fourth quarter and full year 2025.Key Fourth Quarter 2025 Results & Recent Highlights1Net Sales of $1.3 billion, slightly down compared to the corresponding prior-year quarter, with TSS reporting a record fourth quarter with double-digit year-over-year growth of 37% in Opteon™ RefrigerantsNet Loss attributable to Chemours of $47 million, or $0.31 per diluted share, compared with Net Loss attributable to Chemours of $11 million, or $0.08 per diluted share, in the corresponding prior-year quarterAdjusted Net Income2 of $7 million, or $0.05 per diluted share, compared to Adjusted Net Income of $14 million, or $0.09 per diluted share, in the corresponding prior-year quarterAdjusted EBITDA2,3 of $128 million compared to $168 million in the corresponding prior-year quarterImplemented a global TiO2 price increase which became effective December 1, 2025Announced the sale of the former Kuan Yin TiO2 site on January 15, 2026, for approximately $3004 million in net proceedsKey Full Year 2025 Results & Highlights1Net Sales of $5.8 billion, flat compared to the prior year, with TSS reporting record annual sales with double-digit year-over-year growth in Opteon™ RefrigerantsNet Loss attributable to Chemours of $386 million, or $2.57 per diluted share, compared with Net Income attributable to Chemours of $69 million, or $0.46 per diluted share, in the prior yearAdjusted Net Income2 of $143 million, or $0.95 per diluted share, compared to $179 million, or $1.19 per diluted share, in the prior yearAdjusted EBITDA2,3 of $742 million compared to $768 million in the prior yearKey Full Year 2026 Outlook5Consolidated Net Sales growth in the range of 3 to 5%Adjusted EBITDA between $800 million and $900 millionFree Cash Flow Conversion above 25%"Our consolidated fourth quarter results delivered robust cash flow and achieved revenue performance that met our expectations, highlighted by the continued transition to Opteon™ Refrigerants – concluding a record setting year for TSS. However, as a result of short-term cyclical end market headwinds experienced in our APM business, we elected to prioritize cash flow, leading to strong cash generation in the quarter.  In connection with this approach APM incurred a sizable non-cash inventory charge and unfavorable product mix driving our consolidated Adjusted EBITDA slightly below our expected range," said Denise Dignam, Chemours President and CEO. "Although macroeconomic conditions remain tepid, our pricing actions have begun to take effect in TiO2, and we remain focused on executing our broader Pathway to Thrive strategy. The sale of our Kuan Yin TiO2 site, along with increased organic cash flow generation in 2026, will provide significant cash inflow in 2026.  These actions align with our capital allocation priorities under Pathway to Thrive, specifically improving our debt profile and progressing Chemours closer to our long-term objective of net leverage below three times adjusted EBITDA across economic cycles."Total Chemours
Q4 2025Q4 2024Y-o-Y %  
?Q3 2025Q-o-Q %
?FY 2025FY 2024Y-o-Y %
?Net Sales (millions)$1,329$1,359(2 %)$1,495(11 %)$5,808$5,7820 %Net Income (Loss) (millions)($47)($11)(327 %)$46(202 %)($386)$69(659 %)EPS6($0.31)($0.08)(288 %)$0.31(200 %)($2.57)$0.46(659 %)Adjusted EPS$0.05$0.09(46 %)$0.17(71 %)$0.95$1.19(20 %)Adjusted EBITDA (millions)$128$168(24 %)$189(32 %)$742$768(3 %)Fourth quarter 2025 Net Sales were $1.3 billion, down 2% compared to the prior-year quarter. Reported Net Sales were primarily driven by a 4% decrease in volume, partially offset by a 1% increase in price and a 1% currency tailwind. The decrease in volume was primarily driven by weaker cyclically-sensitive end markets impacting both TT and APM, partially offset by the continued strength in TSS volume tied to increased Opteon™ Refrigerants adoption.Fourth quarter 2025 Net Loss attributable to Chemours was $47 million, or $0.31 per diluted share, compared to Net Loss attributable to Chemours of $11 million, or $0.08 per diluted share in the prior-year quarter. The larger fourth quarter Net Loss attributable to Chemours was driven by lower cost absorption tied to decreased production levels across APM and TT, a non-cash inventory charge along with an unfavorable product mix in APM, and a higher provision for income taxes. Adjusted EBITDA for the fourth quarter of 2025 was $128 million, compared to $168 million in the prior-year quarter driven by the same higher costs impacting the current quarter Net Loss attributable to Chemours.Full year 2025 Net Sales were $5.8 billion, flat compared to the prior year. Net Sales were primarily driven by higher volume and price in TSS and favorable currency movements, partially offset by lower TT pricing.Full year 2025 Net Loss attributable to Chemours was $386 million, or $2.57 per diluted share, compared to Net Income attributable to Chemours of $69 million, or $0.46 per diluted share in the prior year, primarily driven by litigation-related charges inclusive of the announced settlement with the State of New Jersey. Adjusted EBITDA for the year was $742 million, compared to $768 million in the prior year. This decrease was primarily driven by lower TT pricing and lower cost absorption tied to lower production levels concentrated in APM and TT partially offset by volume and price increases in TSS and global net cost reduction efforts7.Thermal & Specialized Solutions
Q4 2025Q4 2024Y-o-Y %
?Q3 2025Q-o-Q %
?FY 2025FY 2024Y-o-Y %
?Net Sales (millions)$444$39014 %$560(21 %)$2,066$1,83013 %Opteon™ Refrigerants$243$17837 %$368(34 %)$1,264$81056 %Freon™ Refrigerants$113$124(10 %)$9419 %$428$614(30 %)Foam, Propellants & Other (FP&O)$87$880 %$98(10 %)$374$406(8 %)Adjusted EBITDA (millions)$128$1225 %$194(34 %)$670$57118 %Adjusted EBITDA Margin29 %31 %(3) ppts35 %(6) ppts32 %31 %1 pptsTSS segment fourth quarter 2025 Net Sales were $444 million, an increase of 14% versus the prior-year quarter, driven by a 10% increase in price and a 3% increase in volume, with a 1% currency tailwind.Increased pricing was driven by a favorable Opteon™ Refrigerant blends mix paired with higher pricing associated with opportunistic Freon™ refrigerant sales.  Volume growth was driven by sustained robust demand for Opteon™ Refrigerant blends associated with the U.S. AIM Act stationary AC transition, which more than compensated for lower total Freon™ Refrigerant volumes.Adjusted EBITDA for the quarter increased 5% to $128 million, while Adjusted EBITDA Margin declined three points to 29%. The increase in Adjusted EBITDA was driven by a favorable Opteon™ Refrigerant blends mix in pricing paired with higher pricing associated with opportunistic Freon™ sales, partially offset by higher input costs associated with R32, a key component of our stationary Opteon™ Refrigerant blends, in the quarter.Sequentially, Net Sales declined 21%, driven by a 22% seasonal volume decrease, partially offset by a 1% price increase. Volumes followed seasonal patterns, declining across refrigerants with some offset in increased demand in certain Freon™ refrigerants.TSS segment full year 2025 Net Sales were a record of $2.1 billion, an increase of 13% from 2024, reflecting sustained robust Opteon™ Refrigerants adoption, with 56% growth, associated with the U.S. AIM Act stationary AC transition. Full year Adjusted EBITDA increased 18% to $670 million, driven by increased Opteon™ volumes and higher prices throughout the portfolio; however, this was partially offset by the referenced increased input costs related to R32.Titanium Technologies
Q4 2025Q4 2024Y-o-Y %
?Q3 2025Q-o-Q %
?FY 2025FY 2024Y-o-Y %
?Net Sales (millions)$561$632(11 %)$612(8 %)$2,429$2,572(6 %) TiO2 Pigment$534$598(11 %)$591(10 %)$2,331$2,446(5 %) Minerals$27$34(18 %)$2133 %$98$126(22 %)Adjusted EBITDA (millions)$23$70(67 %)$25(8 %)$145$301(52 %)Adjusted EBITDA Margin4 %11 %(7) ppts4 %0 ppts6 %12 %(6) pptsTT segment fourth quarter 2025 Net Sales were $561 million, an 11% decrease compared to the prior-year quarter. This decrease was primarily driven by a 6% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Lower TiO2 pigment pricing and volumes were paired with lower minerals sales compared to the prior-year quarter. The decrease in TiO2 pigment pricing was mostly concentrated in non-western markets, while pricing declines in protected western markets were less pronounced. Volumes showed a 6% decrease globally, driven by lower sales in non-western markets as the overall TiO2 market continues to remain challenged.TT segment fourth quarter 2025 Adjusted EBITDA decreased 67% to $23 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased seven percentage points to 4%. The decline in Adjusted EBITDA was primarily driven by the referenced pricing trends, combined with lower cost absorption tied to lower production levels. These adjustments to production levels were made to prioritize cash generation given the challenged near-term demand environment.Sequentially, TT segment fourth quarter 2025 Net Sales decreased 8%, driven by an 8% decrease in volume due to seasonality in western markets paired with some destocking activity by North American customers and weaker demand conditions in non-western markets. Global pricing showed stability in connection with the positive results we have seen from the pricing action announced in December of 2025, setting a strong foundation for 2026. Currency fluctuations were approximately flat.TT segment full year 2025 Net Sales were $2.4 billion, a 6% decrease compared to full year 2024. The decrease in Net Sales was primarily driven by global pricing stemming from a weaker demand environment. TT segment full year Adjusted EBITDA decreased 52% from the prior year to $145 million. This decrease was also primarily driven by global pricing tied to the weaker demand environment, paired with lower cost absorption related to decisions to reduce production levels to promote cash flow generation and operational disruption impacts that occurred in the year.Advanced Performance Materials
Q4 2025Q4 2024Y-o-Y %
?Q3 2025Q-o-Q %
?FY 2025FY 2024Y-o-Y %
? Net Sales (millions)$312$324(4 %)$3110 %$1,263$1,326(5 %)Advanced Materials$172$191(10 %)$190(10 %)$753$808(7 %)Performance Solutions$141$1336 %$12116 %$510$518(2 %)Adjusted EBITDA (millions)$12$47(74 %)$14(12 %)$108$160(32 %)Adjusted EBITDA Margin4 %15 %(11) ppt4 %0 ppts9 %12 %(3) pptsAPM segment fourth quarter 2025 Net Sales were $312 million, a 4% decrease compared to the prior-year quarter. This decrease was primarily driven by an 8% decrease in volume which was partially offset by a 3% increase in price. The volume decline was primarily driven by the recent closure of APM's Advanced Materials SPS Capstone™ line, completed in the third quarter.APM segment fourth quarter 2025 Adjusted EBITDA decreased 74% to $12 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased eleven percentage points to 4%. The decrease in Adjusted EBITDA was primarily driven by a decision to prioritize cash generation in the business given cyclical end market weakness, which lead to a non-cash inventory charge of approximately $17 million, a smaller idling charge, as well as approximately $10 million tied to product sales at a less favorable mix to reduce inventory and promote cash flow.Sequentially, APM segment fourth quarter 2025 Net Sales were roughly flat, with increased volumes in Performance Solutions more than offsetting lower sequential Advanced Materials volumes due to the recent line closure.APM segment full year 2025 Net Sales were $1.3 billion, a 5% decrease compared to full year 2024. This decrease was primarily driven by weaker global demand across cyclically sensitive end markets. Adjusted EBITDA decreased 32% from the prior year to $108 million. This decrease was primarily driven by lower cost absorption tied to lower production and operational disruption impacts during the year.Other Non-Reportable SegmentThe Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the fourth quarter 2025 of $12 million and $1 million, respectively. Full year results for the Company's Other Non-Reportable Segment amounted to Net Sales of $50 million and Adjusted EBITDA of $8 million.Corporate Expenses8Corporate Expenses were $33 million in the fourth quarter 2025, a decrease of approximately $36 million compared to the prior-year quarter. This was primarily due to lower costs associated with litigation activities and the Company's continued cost reduction efforts under its Pathway to Thrive strategy.Liquidity and Capital AllocationAs of December 31, 2025, consolidated gross debt was $4.2 billion. Debt, net of $670 million in unrestricted cash and cash equivalents, was $3.5 billion, resulting in a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.6 billion, comprised of $670 million in unrestricted9 cash and cash equivalents and $955 million of revolving credit facility capacity, net of outstanding letters of credit.Cash provided by operating activities for the fourth quarter of 2025 was $137 million, compared to $138 million in the prior-year quarter.Capital expenditures for the fourth quarter of 2025 amounted to $45 million, a decrease in spend compared to $109 million in the prior-year quarter, driven by lower capital expenditures in APM and TSS.Free Cash Flows for the fourth quarter of 2025 were $92 million, reflecting Free Cash Flow Conversion of 72%, compared to $29 million, or 17% Free Cash Flow Conversion, in the fourth quarter of 2024.First Quarter 2026 OutlookIn the first quarter, the Company anticipates consolidated Net Sales to increase in the range of 3 to 5% sequentially driven by TSS, with consolidated Adjusted EBITDA expected to range between $120 million and $150 million. Corporate Expenses are expected to approximate $45 million to $50 million. The Company also anticipates capital expenditures to be in the $50 million range, with Free Cash Flows reflecting a use of cash not to exceed $100 million.TSS projects Net Sales will rise sequentially in the mid-twenty to thirty percentage range, mainly due to more favorable seasonal refrigerant demand and an expected 30 to 40% increase in Opteon™ Refrigerants sales from ongoing adoption in North America's stationary market. Adjusted EBITDA is expected to be between $170 million and $185 million, also driven by the referenced seasonality strength and  continued equipment transition.TT expects an overall sequential Net Sales decrease in the low-to-mid-single digits percentage range. Total minerals sales are anticipated to decline 60% in the first quarter due to sales timing and impacts from recent changes in mining efforts. TiO2 pigment revenues are anticipated to be down low-single digits sequentially, due to weaker seasonal volumes in non-western markets more than offsetting volume increases in western markets and the global pricing efforts highlighted last quarter. Adjusted EBITDA is expected to be between break-even and $5 million driven by the timing of mining sales paired with approximately $17 million in net higher cost impacts for the quarter related to changes in production levels as well as ore mix.APM expects a sequential Net Sales decrease in the high-teens percentage range, driven by weakness in key end markets, combined with customer timing and constraints from an outage at our Washington Works facility. Adjusted EBITDA for APM is expected to be between break even and $5 million, driven by the referenced outage, which is anticipated to approximate $20 million to $25 million of earnings impacts in the first quarter, the majority of which is driven by sales constraints tied to the facility outage.Full Year 2026 OutlookThe Company expects to deliver 2026 Net Sales growth in the range of 3 to 5% and Adjusted EBITDA of $800 million to $900 million, primarily driven by increased TSS and APM Performance Solutions demand, expected pricing strength in TT, and further benefitted by continued cost improvement realization in TT and APM throughout the year.  Capital expenditures are anticipated to range from $275 million to $325 million, with an overall Free Cash Flow Conversion above 25% from improved earnings and working capital improvements throughout the year.Conference CallAs previously announced, Chemours will hold a conference call and webcast on February 20, 2026, at 8:00 AM Eastern Time. The webcast and materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours' investor website.About The Chemours CompanyThe Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.Non-GAAP Financial MeasuresWe prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.Forward-Looking StatementsThis press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the first quarter of 2026, the full year 2026 and the Company's refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the United States or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the United States or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the United States or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.CONTACTS:INVESTORS 
Brandon Ontjes 
Vice President, Head of Strategy & Investor Relations 
+1.302.773.3309
investor@chemours.com  NEWS MEDIA 
Cassie Olszewski
Media Relations & Reputation Leader 
+1.302.219.7140
media@chemours.com_____________________________1Certain prior period amounts have been revised to correct for certain immaterial errors which will be further described in our Annual Report on Form 10-K for the year ended December 31, 2025.2Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".3Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.4Reflects TWD to USD exchange rate as of the time of this release, and reflects total proceeds net of related transaction and tax impacts5For information on our outlook non-GAAP measures, please refer to the attached "Reconciliation of GAAP Measures to Non-GAAP Financial Measures (unaudited)"6On a diluted earnings per share basis7Excluding litigation settlements recognized in the year ended December 31, 202582025 consolidated Adjusted EBITDA also reflects additional unallocated costs of $5 million and $8 million in Q4 2025 and year ended 2025, respectively. These costs are reflected in consolidated Adjusted EBITDA results only.9Restricted cash approximated $54 million as of the end of the fourth quarter of 2025, reflecting primarily escrow payments Chemours has made related to the MOU agreement with DuPont, Corteva and EID will be further described in our Annual Report on Form 10-K for the year ended December 31, 2025. The Chemours CompanyConsolidated Statements of Operations (Unaudited)1(Dollars in millions, except per share amounts) 

Year Ended December 31,


2025

2024

2023
Net sales
$5,808

$5,782

$6,078
Cost of goods sold

4,906


4,640


4,776
Gross profit

902


1,142


1,302
Selling, general, and administrative expense

799


598


1,286
Research and development expense

108


109


108
Restructuring, asset-related, and other charges

59


60


153
Goodwill impairment charge

—


56


—
Total other operating expenses

966


823


1,547
Equity in earnings of affiliates

35


43


45
Interest expense, net

(269)


(263)


(208)
Loss on extinguishment of debt

(5)


(1)


(1)
Other income, net

26


8


91
(Loss) income before income taxes

(277)


106


(318)
Provision for (benefit from) income taxes

109


37


(66)
Net (loss) income

(386)


69


(252)
Less: Net income attributable to non-controlling interests

—


—


1
Net (loss) income attributable to Chemours
$(386)

$69

$(253)
Per share data








Basic (loss) earnings per share of common stock
$(2.57)

$0.46

$(1.70)
Diluted (loss) earnings per share of common stock

(2.57)


0.46


(1.70)
 The Chemours CompanyConsolidated Balance Sheets (Unaudited)1(Dollars in millions, except per share amounts) 

December 31,


2025

2024
Assets





Current assets:





Cash and cash equivalents
$670

$713
Restricted cash and restricted cash equivalents

2


—
Accounts and notes receivable, net

679


770
Inventories

1,569


1,463
Prepaid expenses and other

80


71
Assets held for sale

1


—
Total current assets

3,001


3,017
Property, plant, and equipment

9,920


9,577
Less: Accumulated depreciation

(6,842)


(6,389)
Property, plant, and equipment, net

3,078


3,188
Operating lease right-of-use assets

271


265
Goodwill

46


46
Other intangible assets, net

2


3
Investments in affiliates

160


152
Assets held for sale, non-current

21


—
Restricted cash and restricted cash equivalents

52


50
Other assets

751


788
Total assets
$7,382

$7,509
Liabilities





Current liabilities:





Accounts payable
$954

$1,156
Compensation and other employee-related cost

96


99
Short-term and current maturities of long-term debt

42


54
Current environmental remediation

88


115
Other accrued liabilities

506


396
Total current liabilities

1,686


1,820
Long-term debt, net

4,099


4,059
Operating lease liabilities

191


198
Long-term environmental remediation

530


456
Deferred income taxes

37


35
Other liabilities

588


369
Total liabilities

7,131


6,937
Commitments and contingent liabilities





Equity





Common stock (par value $0.01 per share; 810,000,000 shares authorized;
198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025;
198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024)

2


2
Treasury stock, at cost (48,826,793 shares at December 31, 2025; 48,871,602 shares at
December 31, 2024)

(1,802)


(1,804)
Additional paid-in capital

1,074


1,055
Retained earnings

1,220


1,685
Accumulated other comprehensive loss

(244)


(367)
Total Chemours stockholders' equity

250


571
Non-controlling interests

1


1
Total equity

251


572
Total liabilities and equity
$7,382

$7,509
 The Chemours CompanyConsolidated Statements of Cash Flows (Unaudited)1(Dollars in millions) 

Year Ended December 31,


2025

2024

2023
Cash flows from operating activities








Net (loss) income
$(386)

$69

$(252)
Adjustments to reconcile net income to cash provided by operating activities:








Depreciation and amortization

340


292


309
Gain on sales of assets and businesses, net

(8)


(3)


(110)
Equity in earnings of affiliates, net

(7)


(1)


11
Loss (gain) on extinguishment of debt

5


1


1
Amortization of debt issuance costs and issue discounts

11


12


9
Deferred tax provision (benefit)

64


(31)


(143)
Asset-related charges

32


27


95
Stock-based compensation expense

21


15


18
Net periodic pension (income) cost

(2)


6


9
Defined benefit plan contributions

(2)


(12)


(10)
Other operating charges and credits, net

18


(42)


1
Goodwill impairment

—


56


—
Decrease (increase) in operating assets:








Accounts and notes receivable, net

106


(139)


(14)
Inventories and other current operating assets

(106)


(140)


61
Other non-current operating assets

66


(98)


—
(Decrease) increase in operating liabilities:








Accounts payable

(165)


4


(74)
Other current operating liabilities

(3)


(660)


642
Non-current operating liabilities

280


11


3
Cash provided by (used for) operating activities

264


(633)


556
Cash flows from investing activities








Purchases of property, plant, and equipment

(213)


(360)


(370)
Proceeds from sales of assets and businesses, net of cash divested

7


3


143
Foreign exchange contract settlements, net

(1)


2


(8)
Other investing activities

1


2


6
Cash used for investing activities

(206)


(353)


(229)
Cash flows from financing activities








Proceeds from issuance of debt, net

748


606


648
Debt repayments

(787)


(490)


(280)
Payments of debt issuance costs

(7)


(9)


(4)
Payments on finance leases

(14)


(12)


(11)
Proceeds from supplier financing programs

80


93


123
Payments to supplier financing program

(88)


(102)


(87)
Purchases of treasury stock, at cost

—


—


(69)
Proceeds from exercised stock options

—


9


19
Payments related to tax withheld on vested stock awards

(1)


(3)


(19)
Payments of dividends to the Company's common shareholders

(78)


(148)


(149)
(Distributions to) cash received from non-controlling interest shareholders

—


(1)


1
Other financing activities

21


21


—
Cash (used for) provided by financing activities

(126)


(36)


172
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents

29


(22)


4
(Decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents

(39)


(1,044)


503
Cash, cash equivalents, restricted cash, and restricted cash equivalents at January 1,

763


1,807


1,304
Cash, cash equivalents, restricted cash, and restricted cash equivalents at December 31,
$724

$763

$1,807










Supplemental cash flows information








Cash paid during the year for:








Interest, net of amounts capitalized
$251

$267

$223
Income taxes, net of refunds

74


82


63
Non-cash investing and financing activities:








Purchases of property, plant, and equipment included in accounts payable
$33

$88

$82
Treasury stock repurchased, not settled

—


—


—
 The Chemours CompanySegment Financial and Operating Data (Unaudited)(Dollars in millions) Segment Net Sales (1)











Three Months











Ended

Sequential

Three Months Ended December 31,

Increase /

September 30,

Increase /

2025

2024

(Decrease)

2025

(Decrease)
Thermal & Specialized Solutions$
444

$
390

$
54

$
560

$
(116)
Titanium Technologies

561



632



(71)



612



(51)
Advanced Performance Materials

312



324



(12)



311



1
Other Segment

12



13



(1)



12



—
Total Net Sales$
1,329

$
1,359

$
(30)

$
1,495

$
(166)
 Segment Adjusted EBITDA








Three Months

















Ended

Sequential

Three Months Ended December 31,

Increase /

September 30,

Increase /

2025

2024

(Decrease)

2025

(Decrease)
Thermal & Specialized Solutions$
128

$
122

$
6

$
194

$
(66)
Titanium Technologies$
23

$
70

$
(47)

$
25

$
(2)
Advanced Performance Materials$
12

$
47

$
(35)

$
14

$
(2)
Other Segment$
1

$
—

$
1

$
2

$
(1)
 Quarterly Change in Net Sales from the three months ended December 31, 2024
















December 31,
2025

Percentage Change
vs.
Percentage Change Due To

Net Sales

December 31, 2024
Price
Volume
Currency
Portfolio
Total Company$
1,329


(2)%
1%
(4)%
1%
—%














Thermal & Specialized Solutions$
444


14%
10%
3%
1%
—%Titanium Technologies

561


(11)%
(6)%
(6)%
1%
—%Advanced Performance Materials

312


(4)%
3%
(8)%
1%
—%Other Segment

12


(10)%
(7)%
(3)%
—%
—% Quarterly Change in Net Sales from the three months ended September 30, 2025
















December 31,
2025

Percentage Change
vs.
Percentage Change Due To

Net Sales

September 30, 2025
Price
Volume
Currency
Portfolio
Total Company$
1,329


(11)%
1%
(12)%
—%
—%














Thermal & Specialized Solutions$
444


(21)%
1%
(22)%
—%
—%Titanium Technologies

561


(8)%
—%
(8)%
—%
—%Advanced Performance Materials

312


—%
—%
—%
—%
—%Other Segment

12


—%
—%
—%
—%
—% The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions)GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation1Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as income (loss) before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net income (loss) attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

Three Months Ended

Year Ended


December 31,

September 30,

December 31,


2025

2024

2025

2025

2024
Income (loss) before income taxes
$
(67)

$
1

$
38

$
(277)

$
106
Net (loss) income attributable to Chemours
$
(47)

$
(11)

$
46

$
(386)

$
69
Non-operating pension and other post-retirement employee benefit (income) cost


(3)



1



(4)



(10)



(3)
Exchange losses, net


4



3



1



11



9
Restructuring, asset-related, and other charges (1)


4



7



4



58



58
Goodwill impairment charge (2)


—



—



—



—



56
Loss on extinguishment of debt


5



1



—



5



1
Gain on sales of assets and businesses, net (3)


—



—



(7)



(8)



(3)
Transaction costs (4)


4



2



—



6



2
Qualified spend recovery (5)


(7)



(4)



(13)



(42)



(26)
Litigation-related charges (6)


19



—



8



320



(2)
Environmental charges (7)


20



15



13



93



15
Adjustments made to income taxes (8)


19



6



(18)



182



9
Benefit from income taxes relating to reconciling items (9)


(11)



(6)



(4)



(86)



(6)
Adjusted Net Income


7



14



26



143



179
Net income attributable to non-controlling interests


(1)



—



—



—



—
Interest expense, net


68



67



68



269



263
Depreciation and amortization (10)


81



75



80



317



292
All remaining (benefit from) provision for income taxes (9)


(27)



12



15



13



34
Adjusted EBITDA
$
128

$
168

$
189

$
742

$
768





















Total debt principal












$
4,182

$
4,156
Less: Cash and cash equivalents














(670)



(713)
Total debt principal, net












$
3,512

$
3,443





















Net Leverage Ratio (calculated using GAAP earnings) (11)













(12.7)x


32.5x
Net Leverage Ratio (calculated using Non-GAAP earnings) (11)













4.7x


4.5x
 GAAP Net Income (Loss) Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation
GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)1(1)For the year ended December 31, 2025, restructuring, asset-related and other charges primarily includes charges related to our decision to exit our SPS Capstone™ business and the 2024 Restructuring Program. For the year ended December 31, 2024, restructuring, asset-related and other charges primarily includes charges related to the 2024 Restructuring Program and the Titanium Technologies Transformation Plan. See "Note 7 –Restructuring, Asset-Related and Other Charges" to the Consolidated Financial Statements in our Quarterly Report on Form 10-K for the year ended December 31, 2025 for further details.(2)Represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2024.(3)For the year ended December 31, 2025, gain on sales of assets and businesses, net includes a gain on sale of $7 million related to certain parcels of land at the Company's manufacturing site in Kuan Yin, Taiwan.(4)For the year ended December 31, 2025, transaction costs includes $4 million of costs associated with the Senior Secured Credit Facilities. See "Note 20 – Debt" to the Consolidated Financial Statements in our Quarterly Report on Form 10-K for the year ended December 31, 2025 for further details.(5)Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 2 – Commitments and Contingent Liabilities" to the Consolidated Financial Statements in our Quarterly Report on Form 10-K for the year ended December 31, 2025.(6)Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the year ended December 31, 2025, litigation-related charges primarily includes $270 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $12 million in third-party legal fees directly related to the New Jersey Settlement agreement, $14 million related to the Company's portion of Chemours, DuPont, Corteva, EID's settlement agreement to resolve the Hoosick Falls class action lawsuit and $18 million related to reserves for asbestos and production liability matters. For the year ended December 31, 2024, litigation-related charges includes $44 million of benefits from insurance recoveries, along with the $29 million accrual for the Ohio MDL. See "Note 22 – Commitments and Contingent Liabilities" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025 for further details.(7)Environmental charges pertains to management's assessment of estimated liabilities associated with certain non-recurring environmental remediation expenses at various sites. For the year ended December 31, 2025, environmental charges primarily includes changes in remediation reserves at the four sites covered by the New Jersey settlement agreement. For the year ended December 31, 2024, environmental charges primarily includes off-site remediation costs at Dordrecht Works. See "Note 22 – Commitments and Contingent Liabilities" to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2025 for further details.(8)Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.(9)The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.(10)For the year ended December 31, 2025, accelerated depreciation charges of $23 million incurred as part of our decision to exit our SPS Capstone™ business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.(11)Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by income (loss) before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation1Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.

Three Months Ended
Year Ended

December 31,
September 30,
December 31,

2025
2024
2025
2025
2024Numerator:










Net (loss) income attributable to Chemours
$(47)
$(11)
$46
$(386)
$69Adjusted Net Income

7

14

26

143

179Denominator:









Weighted-average number of common shares outstanding - basic

150,464,150

149,825,988

150,320,265

150,237,101

149,494,462Dilutive effect of the Company's employee compensation plans (1)

398,511

503,667

461,349

404,781

677,827Weighted-average number of common shares outstanding - diluted (1)

150,862,661

150,329,655

150,781,614

150,641,882

150,172,289










Basic (loss) earnings per share of common stock (2)
$(0.31)
$(0.08)
$0.31
$(2.57)
$0.46Diluted (loss) earnings per share of common stock (1) (2)

(0.31)

(0.08)

0.31

(2.57)

0.46Adjusted basic earnings per share of common stock (2)

0.05

0.09

0.17

0.95

1.20Adjusted diluted earnings per share of common stock (1) (2)

0.05

0.09

0.17

0.95

1.19

(1)In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three months ended December 31, 2025 and December 31, 2024, as well as the year ended December 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three months ended December 31, 2025 and December 31, 2024, as well as the year ended December 31, 2025 as Adjusted Net Income was in a net income position.(2)Figures may not recalculate exactly due to rounding. Basic and diluted earnings (loss) per share are calculated based on unrounded numbers.GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation
Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

Three Months Ended

Year Ended


December 31,

September 30,

December 31,


2025

2024

2025

2025

2024
Cash flows provided by (used for) operating activities
$
137

$
138

$
146

$
264

$
(633)
Less: Purchases of property, plant, and equipment


(45)



(109)



(41)



(213)



(360)
Free Cash Flows
$
92

$
29

$
105

$
51

$
(993)
Adjusted EBITDA


128



168



189



742



768
Free Cash Flow Conversion


72%


17%


56%


7%


(129)%The Chemours Company
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)
(Dollars in millions, except per share amounts)GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion ReconciliationFree Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

Estimated


Year Ended December 31, 2026


Low

High
Cash flows provided by (used for) operating activities
$
475

$
595
Less: Purchases of property, plant, and equipment


(275)



(325)
Free Cash Flows
$
200

$
270
Adjusted EBITDA


800



900
Free Cash Flow Conversion


25%


30%2026 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)

(Estimated)


Year Ending December 31, 2026


Low

High
Net income attributable to Chemours
$165

$225
Restructuring, transaction, and other costs, net (2)

(35)


(45)
Adjusted Net Income

130


180
Interest expense, net

275


285
Depreciation and amortization

315


325
All remaining provision for income taxes

80


110
Adjusted EBITDA
$800

$900
 





View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-reports-fourth-quarter-and-full-year-2025-results-302693114.htmlSOURCE The Chemours Company

Original: The Chemours Company Reports Fourth Quarter and Full Year 2025 Results

Chemours Announces Dates for Fourth Quarter 2025 Earnings Release and Webcast Conference CallFebruary 4, 2026 4:30 PM
PR Newswire (US)

WILMINGTON, Del., Feb. 4, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE: CC) today announced that the Company expects to issue its fourth quarter 2025 financial results after market on Thursday, February 19, 2026.







The Company expects to hold its conference call to discuss its fourth quarter 2025 financial results at 8:00 a.m. Eastern Time on Friday, February 20, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.Conference Call: Please visit investors.chemours.com for a link to the live webcast and to view the accompanying slides.Replay: A webcast replay will be available at investors.chemours.com.About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn. CONTACTS:INVESTORS
Brandon Ontjes
Vice President, Head of Strategy & Investor Relations
+1.302.773.3300 
investor@chemours.com NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
media@chemours.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/chemours-announces-dates-for-fourth-quarter-2025-earnings-release-and-webcast-conference-call-302679446.htmlSOURCE The Chemours Company

Original: Chemours Announces Dates for Fourth Quarter 2025 Earnings Release and Webcast Conference Call

Chemours may have edge in Data Center Cooling

The Trump administration and the United Arab Emirates are partnering to build a massive data center in Abu Dhabi that is expected to be the largest artificial intelligence (AI) campus outside the United States.

The AI campus, unveiled during President Trump’s visit to the UAE, will have 5 gigawatts of capacity and will eventually stretch across 10 square miles, the Commerce Department announced Thursday.

The data center at Qasr Al Watan will serve as a regional platform for U.S. hyperscalers, which are technology companies that provide cloud computing and data management services. These companies will be able to offer low-latency services to nearly half of the global population resigning within 2,000 miles of the UAE, the Commerce Department.

https://www.investorvillage.com/uploads/87669/files/Chemours-FINAL_Immersion-Cooling-Summary-Case-study.pdf

https://en.m.wikipedia.org/wiki/Dark_Waters_(2019_film)

https://www.google.com/amp/s/www.wect.com/2021/03/27/pay-up-lawmaker-wants-chemours-buy-equipment-rid-drinking-water-toxic-chemicals/%3foutputType=amp

Looks like this is the bottom................

https://news.bloombergenvironment.com/environment-and-energy/dupont-owes-50-million-in-latest-pfas-cancer-cases-jury-finds

CC something might really be cooking here. Some big names have been buying and todays move is interesting.

I grabbed a boat load of $17 calls. I love a good lotto to go Bust or Boom with!

News: $CC Chemours' John Sworen Receives Moore Medal for Developing Non-Fluorinated Bio-Based Water Repellent

WILMINGTON, Del. , Sept. 10, 2019 /PRNewswire/ -- John Sworen , a Technical Fellow at The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, today will receive the 2019 SCI Gord...

In case you are interested CC - Chemours' John Sworen Receives Moore Medal for Developing Non-Fluorinated Bio-Based Water Repellent

Traded few times, still lost a little, sold out 19's. Blew threw gap from few years ago was checking out $16's, now staying on the sidelines this one and couple others.

Becoming one of these people nervous about the market in general lately. I am running up my weed stocks hopefully and go to cash, as possible.

Seems like the market now really tough on tickers like CC and runs any hint of headwinds; until recently more forgiving, now punishing them.

Had a great year so far; now wanting to bank and come back later.

gl

Wow- lowered my entry target. Bummed this got so beat up even though I don't own yet.

So sorry, this will interest me around $12.75 at this point. Hope they get it together and their Moody's doesn't get lowered.

BOL!


MY OWN MUSINGS. I DO NOT HAVE A POSITION IN THIS STOCK AS OF THIS POST.

-20%
Not so pretty

Earnings today

Here's what's up CC: https://www.insidernj.com/press-release/sierra-club-lawsuit-shows-dupont-downplays-environmental-liability/

Traded this OK, so not down much so far, but inclined to add lower as they sue Dupont for misrepresenting the cleanups.

gl

5 times earnings, idk happy to own, 4.5% divvy...

I'm going to wait for a little more value-fundamentals seem great, just a little expensive.

Thinking $18-$19.

MY OPINION ONLY.

Watch list long time, buyer again today CC $$...

Agree- its like rooting for the bad guys in a movie!

Chemicals getting hit hard in general. I wouldn't classify CC as a bad company- in fact, I'm bullish on the whole sector LONG TERM.




BOL, I DO NOT HAVE A POSITION IN CC

MY OPINION ONLY!

Lot of people hitting the exit door on this pos it seems

News: $CC Chemours Announces Dates for Fourth Quarter and Full-Year 2018 Earnings Release and Webcast Conference Call

WILMINGTON, Del. , Jan. 24, 2019 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced it will release fourth quarter and full-year 2018 financial...

Find out more https://marketwirenews.com/news-releases/chemours-announces-dates-for-fourth-quarter-and-full-year-2018-earnings-release-and-webcast-conference-call-7549410.html

"The Devil we Know" must see Movie https://thedevilweknow.com/

CC buy 47.64

















normal chart




log chart

52

High volume of buying at the close of business today leading into the earnings disclosure.

Not much MarginOfSafety for Chemours $CC going into earnings Wednesday...

Valuation Source

http://www.citronresearch.com/chemours-is-a-bankruptcy-waiting-to-happen-chemours-was-purposely-designed-for-bankruptcy/

http://finance.yahoo.com/news/u-jury-orders-dupont-pay-160023408.html

The Chemours Company Reports Third Quarter 2016 Results; Significant Earnings and Margins Increases Driven by Progress on Transformation Plan and Improved Market Conditions (11/06/16)

WILMINGTON, Del., Nov. 6, 2016 /PRNewswire/ --

Third Quarter 2016 Highlights

•Net Sales of $1.4 billion

•Net Income of $204 million, or $1.11 per diluted share, including
gain on asset sales of $169 million, impairment charges of $46 million, interest expense of $51 million and restructuring costs of $14 million

•Adjusted EBITDA of $268 million

•Adjusted Net Income of $112 million, or $0.61 per diluted share

Other Highlights

•Continued progress on all transformation plan objectives, including cost reductions, growth initiatives and portfolio rationalization

•Improved cash from operating activities by ~$440 million year-to-date

•Retired $315 million of long term debt through October 31, 2016

•Generated ~$685 million in gross proceeds from Chemical Solutions divestitures

•Increased full-year Adjusted EBITDA outlook to be between $740 and $775 million based on a net income range of approximately $265 to $290 million

The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, today announced financial results for the third quarter 2016.

Chemours President and CEO Mark Vergnano said, "We continue to make excellent progress on all aspects of our transformation plan, realizing an incremental $60 million of cost savings during the quarter. We are benefiting from the OpteonTM refrigerant ramp up and the expansion of our low-cost TiO2 capacity at Altamira, while at the same time, delivering our planned cost reductions." He continued, "We successfully completed the Chemical Solutions portfolio review during the quarter, generating substantial proceeds. And, in the quarter, our Titanium Technologies business benefited from more favorable market conditions, while the fluoropolymers market remained challenged. Transformation initiatives are pervasive throughout the company and our results speak for themselves."

Third quarter net sales were $1.4 billion, a decrease of 6 percent from $1.5 billion in the prior-year quarter, primarily due to the impact of divestitures. Third quarter net income was $204 million, or $1.11 per diluted share, versus net loss of $29 million, or ($0.16) per diluted share in the prior-year quarter. Adjusted EBITDA for the third quarter was $268 million versus $169 million in the prior-year quarter. Benefits from cost reductions, improved average prices in Titanium Technologies and improved profitability in Fluoroproducts was partially offset by the loss of Adjusted EBITDA from the asset sales within Chemical Solutions.

Sequentially, sales increased 1 percent to $1.4 billion in the third quarter. Third quarter net income was $222 million higher, or $1.21 per diluted share, versus the second quarter net loss of $18 million or ($0.10) per diluted share. The sales improvement was largely driven by higher seasonal volumes in Titanium Technologies and Fluoroproducts supplemented by higher TiO2 pricing. Third quarter Adjusted EBITDA increased $81 million from $187 million in the second quarter of 2016. Improved pricing in Titanium Technologies and OpteonTM refrigerant growth in Fluoroproducts were the primary drivers of the improved sequential performance, which were partially offset by unfavorable Corporate and Other expenses.

Titanium Technologies
In the third quarter, Titanium Technologies segment sales were $625 million, a 1 percent increase versus the prior-year quarter. Improved year-over-year global average TiO2 pricing increased sales 2 percent which was partially offset by minimal currency headwinds. Year-over-year, TiO2 volume was higher in all regions outside of China. Segment Adjusted EBITDA was $144 million, an 80 percent increase over the prior-year quarter. The increase in Adjusted EBITDA was primarily due to the benefits of price increases, transformation plan cost savings, and operational efficiencies.

Sequentially, versus the second quarter of 2016, sales increased 5 percent and Adjusted EBITDA increased $33 million, or 30 percent. The increase in sales was due to slightly stronger volumes and a higher global average price increase of approximately 3 percent. A volume increase of 2 percent was the result of stronger demand primarily in Asia and Latin America. Higher Adjusted EBITDA was driven by the benefits of global average price increases, stronger volumes and better utilization resulting in lower costs.

Fluoroproducts
Fluoroproducts segment sales in the third quarter were $591 million, an increase of 3 percent versus the prior-year quarter. A substantial increase in demand for Opteon™ refrigerants was mostly offset by government-imposed volume reductions of base refrigerants as well as competitive pricing pressure within fluoropolymers. Segment Adjusted EBITDA was $143 million, a 57 percent improvement versus the prior-year quarter. Increased contributions from Opteon™ refrigerants and transformation cost reductions were partially offset by unfavorable pricing and mix within our fluoropolymers product lines.

Sequentially, versus the second quarter of 2016, sales and Adjusted EBITDA increased 3 percent and 36 percent, respectively. The Opteon™ refrigerants ramp up and strong demand for certain fluoropolymers products more than offset regulatory-driven lower demand in base refrigerant sales. In addition to Opteon™ refrigerant growth, the increase in Adjusted EBITDA was primarily attributed to cost reductions.

Chemical Solutions
In the third quarter, Chemical Solutions segment sales were $182 million, a 38 percent decline versus the prior-year quarter. Lower sales were driven by the divestitures of the Clean and Disinfect business, Sulfur Products and Beaumont Aniline facility, as well as reduced average prices based on contractual pass-through terms. Segment Adjusted EBITDA was $9 million, $1 million above the prior-year quarter, reflecting lower operating costs partially offset by the impacts of the divestitures.

Sequentially, sales decreased 15 percent versus the second quarter of 2016, while Adjusted EBITDA was $2 million lower driven primarily by portfolio changes completed in the current quarter.

In the third quarter, we completed the sales of Sulfur Products and the Clean and Disinfect business to Veolia and LANXESS, respectively, for combined proceeds of approximately $544 million. Also, consistent with the company's plan to streamline the portfolio and deliver cost savings in 2017, the company ceased production at the Niagara Reactive Metals facility at the end of September.

Corporate and Other
Corporate and Other represented a negative $28 million of Adjusted EBITDA, an increase of $18 million versus the prior-year quarter. Higher expenses were primarily related to performance-related compensation adjustments and other miscellaneous expenses in the quarter. Versus the second quarter of 2016, Corporate and Other expenses declined $12 million largely due to timing of expenses.

The company realized a cash tax rate of approximately 16 percent in the quarter. For the full year 2016, the company expects its cash tax rate to be in the low-twenties on a percentage basis, taking into consideration the company's anticipated geographic mix of earnings and implications of all divestitures during the year.

Liquidity
As of September 30, 2016, gross consolidated debt was $3.8 billion. Debt, net of cash, was $2.8 billion. In the quarter, the company retired approximately $115 million of its bonds. Cash balances were $957 million at September 30, 2016. In October 2016, the company retired an additional $107 million of its bonds, resulting in over $315 million of total long term debt retired year-to-date. As a result, the company expects to save approximately $19 million annually from lower interest obligations.

Improved inventory management along with the start of seasonal working capital unwind drove strong progress in working capital results and led to free cash flow of $132 million, up $124 million versus the previous-year quarter. Year-to-date working capital1 performance and free cash flow improved by $448 million and $601 million, respectively, versus the prior-year.

Outlook
"We remain disciplined and focused on executing our Five-Point Transformation Plan," Vergnano commented. "We expect the transformation plan improvements, along with a stronger price environment for TiO2 and increased OpteonTM refrigerants adoption to continue to enhance earnings, despite loss of earnings from divestitures, base refrigerant sales timing and unfavorable Fluoropolymers mix. We now expect full-year 2016 Adjusted EBITDA to be between $740 million and $775 million. We are pleased with the progress we have made year-to-date, and believe we are in a stronger position as we move forward."

Conference Call
As previously announced, Chemours will hold a conference call and webcast on Monday, November 7, 2016 at 8:30 AM EST. The webcast and additional presentation materials can be accessed by visiting the Events & Presentations page of Chemours' investor website, investors.chemours.com. A webcast replay of the conference call will be available on the Chemours' investor website.

About The Chemours Company
The Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry. Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™. Chemours has approximately 8,000 employees across 25 manufacturing sites serving more than 5,000 customers in North America, Latin America, Asia-Pacific and Europe. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC. For more information please visit chemours.com.

[tables deleted]

http://www.prnewswire.com/news-releases/the-chemours-company-reports-third-quarter-2016-results-significant-earnings-and-margins-increases-driven-by-progress-on-transformation-plan-and-improved-market-conditions-300358103.html

The Chemours Company Announces Second Quarter Results; Reports Substantial Progress on Transformation Plan Initiatives (8/08/16)

WILMINGTON, Del., Aug. 8, 2016 /PRNewswire/ --

Second Quarter 2016 Highlights

•Net Sales of $1.4 billion

•Net Loss of $18 million, or ($0.10) per diluted share, including impairment charges of $63 million, interest expense of $50 million and restructuring costs of $9 million

•Adjusted EBITDA of $187 million

•Adjusted Net Income of $49 million, or $0.27 per diluted share

Other Year-To-Date Highlights

•Continued progress on Five-Point Transformation Plan objectives, including delivery of ~$100 million of cost reductions in the first half of 2016, completion of the strategic review of Chemical Solutions portfolio, commercial startup of Altamira TiO2 capacity expansion and announced investment in additional Opteon™ capacity

•$359 million improvement in cash flow from operating activities in the first half

•Reduced ~$100 million of long term debt year-to-date

•Completed the sale of the Sulfur business to Veolia for approximately $325 million

Today, The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, announced financial results for the second quarter 2016.

Chemours President and CEO Mark Vergnano said, "Our second quarter results reflect our focused execution against our Five-Point Transformation Plan and our drive to deliver on our commitments to all our stakeholders. We have just celebrated our first anniversary as a public company, and we are pleased with the progress we have made in that time to strengthen our business model, reduce costs, and optimize our company portfolio. At this point, we have completed the strategic review of our Chemical Solutions portfolio, closed the sale of our Sulfur business for approximately $325 million and announced the sale of our Clean and Disinfect business for $230 million. We began commercial production at our new TiO2 plant in Altamira, Mexico and have been encouraged by improvement in the titanium technologies segment with increasing TiO2 prices. Overall, I am very pleased that we have delivered approximately $100 million in cost reductions, improved margins, improved our working capital, streamlined our portfolio and modestly improved our balance sheet in the first half of 2016."

Second quarter net sales were $1.4 billion, a decrease of 8 percent from $1.5 billion in the prior-year quarter. Second quarter net loss was $18 million, or ($0.10) per diluted share, versus net loss of $18 million, or ($0.10) per diluted share on a pro forma basis in the prior-year quarter. Adjusted EBITDA for the second quarter was $187 million versus $127 million in the prior-year quarter. Improved profitability in Fluoroproducts and cost reductions throughout the company were partially offset by lower average prices in Titanium Technologies and Chemical Solutions along with approximately $9 million of unfavorable currency movements versus the prior-year quarter.

Sequentially, sales increased by $86 million, an increase of 7 percent from $1.3 billion in the first quarter. Second quarter net loss was $18 million, or ($0.10) per diluted share down from net income of $51 million or $0.28 per diluted share. The net loss was primarily driven by asset impairment charges of $63 million in the second quarter. Second quarter Adjusted EBITDA increased by $59 million versus $128 million in the first quarter of 2016. The improved performance was primarily driven by higher seasonal volumes in Titanium Technologies and Fluoroproducts and supplemented by higher TiO2 pricing and lower costs. These were partially offset by unfavorable Corporate and Other expenses.

Titanium Technologies

In the second quarter, Titanium Technologies segment sales were $596 million, a 7 percent decline versus the prior-year quarter. Lower year-over-year pricing reduced net sales 6 percent and lower volume of non-TiO2 product lines and the timing of TiO2 shipments reduced net sales 1 percent. Strong demand in North America and EMEA was offset by weaker volumes in Asia and Latin America versus the prior-year quarter. Segment Adjusted EBITDA was $111 million, a 22 percent improvement compared to the prior-year quarter. Benefits from cost reductions and operational efficiencies drove the improvement in Adjusted EBITDA, but were partially offset by the lower average prices. Currency movements contributed a moderate benefit in the quarter versus the previous-year quarter.

Sequentially, versus the first quarter of 2016, sales increased 14 percent and Adjusted EBITDA increased $57 million, or 105 percent. The increase in sales was due to seasonally stronger volumes and higher global average price increase of approximately 5 percent. Volume increased 10 percent driven by sequentially higher demand in all regions except Latin America. The benefits of global average price increases, stronger volumes, transformation plan cost savings and a $4 million impact from favorable currency movements drove the increase in Adjusted EBITDA. In August 2016, Chemours communicated to customers in EMEA and Latin America that an additional $150 per tonne price increase will be effective September 1, 2016.

Fluoroproducts

Fluoroproducts segment sales in the second quarter were $573 million, a decrease of 3 percent versus the prior-year quarter. Stronger demand for Opteon™ refrigerants in both Europe and the U.S. delivered a significant increase in volume that was offset by regulated volume reductions of base refrigerants, weaker demand for fluoropolymer products into consumer electronics markets and lower pricing due to product mix. Segment Adjusted EBITDA was $105 million, a 94 percent increase versus the prior-year quarter. Transformation plan cost reductions, improved manufacturing operations and increased Opteon™ refrigerant contributions were partially offset by unfavorable mix of fluoropolymers products and approximately $11 million of unfavorable currency movements versus the prior-year quarter.

Sequentially, versus the first quarter of 2016, sales and Adjusted EBITDA increased 8 percent and 24 percent, respectively. Seasonally stronger refrigerant sales, along with continued ramp up in Opteon™ refrigerant volumes, more than offset weaker prices related to unfavorable mix of fluoropolymer sales. The increase in Adjusted EBITDA was driven by Opteon™ refrigerant growth, lower costs and approximately $4 million of benefit from currency movements in the quarter that were partially offset by the unfavorable product mix.

Chemical Solutions

In the second quarter, Chemical Solutions segment sales were $214 million, a 23 percent decline versus the prior-year quarter, primarily due to pass-through impact on prices of lower raw material costs and the portfolio impact of the Beaumont, TX aniline facility sale. Segment Adjusted EBITDA was $11 million, $7 million above the prior-year quarter, reflecting continued benefits from transformation plan initiatives that are lowering operating costs across the segment. The timing of the planned cyanide expansion has been pushed back due to permitting delays, and Chemours now expects the majority of capital expenditures related to the construction will take place in 2017.

Sequentially, sales decreased 13 percent versus the first quarter of 2016 primarily as a result of pass-through pricing, while Adjusted EBITDA was $1 million higher driven primarily by lower operating costs in the second quarter.

In the second quarter, the company completed its strategic review of the Chemicals Solutions segment. On July 29, 2016, the company completed the sale of its Sulfur business to Veolia for approximately $325 million. Chemours expects to close the sale of the Clean and Disinfect (C&D) business to LANXESS for $230 million in the second half of 2016. During the second quarter, activities to shut down the Reactive Metals business in Niagara, NY continued with expected closure by the end of this year.

Corporate and Other

Corporate and Other represented a negative $40 million of Adjusted EBITDA. Corporate and Other expenses in the second quarter of 2016 increased $18 million and $19 million versus the prior-year quarter and the first quarter 2016, respectively. The increase in expenses primarily related to performance-related compensation adjustments, litigation and other miscellaneous expenses in the quarter.

The company recognized a cash tax rate of approximately 25 percent in the quarter, excluding restructuring and other nonrecurring charges. For the full year 2016, the company expects its cash tax rate to be in the high-teens percentages, taking into consideration the company's anticipated geographic mix of earnings and additional implications anticipated with the Sulfur and C&D transactions.

Liquidity

As of June 30, 2016, gross consolidated debt was $3.9 billion. Debt, net of cash, was $3.5 billion.

Cash balances were $383 million at June 30, 2016. In the quarter, the company retired $50 million of Term Loan B and $42 million of its bonds for a combined cash amount of $85 million. An additional $8 million of bonds were retired in July 2016, completing $100 million of total long term debt repurchased year-to-date. As a result of these purchases, the company expects to save approximately $5 million annually from lower interest obligations.

Excluding the impact of interest payments in the quarter, the company continued to improve working capital performance through better inventory management and collections and payables processes. Year-to-date working capital1 performance and free cash flow improved by $219 million and $347 million, respectively, versus the prior-year, not including the benefit of the DuPont prepayment originally received in February 2016.

Outlook

"We are gaining momentum this year from the success of our transformation plan, including cost reductions, portfolio optimization, the ramp up of Opteon™ products and the expansion at Altamira," Vergnano continued. "We expect these initiatives along with our TiO2 price increases will deliver full-year Adjusted EBITDA greater than 2015 and generate modestly positive free cash flow. At this point in the year, we believe that our full-year capital expenditures are tracking slightly below $400 million, primarily due to the shift in the timing of the cyanide expansion. We intend to increase our investment in our Corpus Christi site to add flexibility for our anticipated Opteon™ expansion. We are also investing in other high-return capital projects that will enhance opportunities in our core businesses. We have gained confidence in our ability to realize our transformation plan goals of delivering $350 million of cost reductions and $150 million in Adjusted EBITDA associated with Opteon™ and Altamira through 2017. We believe that we are increasingly well-positioned to continue to strengthen our balance sheet and enhance Chemours' market leadership as we move forward."

Conference Call

As previously announced, Chemours will hold a conference call and webcast on Tuesday, August 9, 2016 at 8:30 AM EDT. The webcast and additional presentation materials can be accessed by visiting the Events & Presentations page of the Chemours investor website, investors.chemours.com. A webcast replay of the conference call will be available on the Chemours investor website.

1 Excludes $131 million of benefit from DuPont prepayment.
— — — — — — — — — — —

About The Chemours Company

The Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry. Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™. Chemours has approximately 8,000 employees across 35 manufacturing sites serving more than 5,000 customers in North America, Latin America, Asia-Pacific and Europe. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC. For more information please visit chemours.com.

http://www.prnewswire.com/news-releases/the-chemours-company-announces-second-quarter-results-reports-substantial-progress-on-transformation-plan-initiatives-300310818.html

Morally bankrupt?
http://www.citronresearch.com/chemours-is-a-bankruptcy-waiting-to-happen-chemours-was-purposely-designed-for-bankruptcy/

Chemours Signs Definitive Agreement to Sell Sulfur Products to Veolia (6/14/16)

Agreement Marks Completion of Chemical Solutions Portfolio Review--Part of Chemours Transformation Plan

WILMINGTON, Del., June 14, 2016 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, has signed a definitive agreement to sell the assets which comprise its Sulfur Products business, part of its Chemical Solutions segment, to Veolia North America for $325 million in cash. The company anticipates closing the transaction within the second half of 2016, subject to customary closing conditions and regulatory approvals.

"Today marks the completion of our Chemical Solutions portfolio review—a key milestone in our five-point transformation plan," said Mark Vergnano, Chemours president and CEO. "In less than one year, we sold our aniline facility in Beaumont, Texas; began cost improvement efforts in our Methylamines business in Belle, W.Va.; began shutdown of our Reactive Metals Business in Niagara Falls, N.Y.; and announced the sale of our Clean and Disinfect and Sulfur businesses. Once complete, we will have a lower capital-intensive and streamlined Chemical Solutions portfolio that includes our growing Cyanides business. The total gross proceeds from the three divestitures will be approximately $700 million, providing strategic flexibility as Chemours completes its transformation plan."

Sulfur Products, with approximately $250 million in revenue, is a leading provider of sulfuric acid products and services to a range of industries in North America. It is a leading provider of spent acid regeneration (SAR) and sulfur gas recovery (SGR) services, non-fuming sulfuric acid and higher value sulfur derivatives (HVSDs). There are approximately 240 employees supporting Sulfur Products primarily located at 7 production sites in North America.

Barclays is acting as financial advisor and Wachtell, Lipton, Rosen & Katz is acting as legal advisor to Chemours.

About The Chemours Company
The Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry. Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™. Chemours has approximately 8,000 employees across 35 manufacturing sites serving more than 5,000 customers in North America, Latin America, Asia-Pacific and Europe. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC. For more information please visit chemours.com.

http://www.prnewswire.com/news-releases/chemours-signs-definitive-agreement-to-sell-sulfur-products-to-veolia-300284173.html

Chemours: DuPont Spinoff ‘Was Purposely Designed for Bankruptcy,’ Citron Says (6/02/16)

By Ben Levisohn

Shares of Chemours (CC) have tumbled more than 7% today after Citron Research issued a report calling the DuPont (DD) spinoff “a bankruptcy waiting to happen,” one that was “purposely designed for bankruptcy.” From the report:

It is obvious to Citron, and many other journalistic outlets, that the whole purpose of Chemours existence was so DuPont could rid itself of the black hole of environmental liabilities that will drag down the company for years if not decades to come.

No one has an exact dollar figure yet on the extent of the liabilities of this debacle. While Chemours only accounts for $20 million of overhang on its balance sheet, most Wall Street analysts estimate the liability to fall more inline with the $500 million figure.

But we always hear the value $5 billion being thrown around by social activists like the “Keep Your Promises DuPont” campaign, which has pegged environmental costs just for Parkersburg WV at $1 billion. After speaking in depth with community activists, Citron believes that even $5 billion may be a low number for
Medical Monitoring
Cleanup
Compensatory damages to victims
Punitive damages to victims
Legal Fees

These damages will be not limited to West Virginia but rather they will span across 171 sites in the U.S, plus worldwide locations. What we are witnessing in the Mid-Ohio Valley is just the tip of the iceberg…

DuPont has agreed to merge with Dow Chemical (DOW). Anticipated completion is this summer. The subsequent plan is for the new entity to be spun off into three separate companies within 18 months.

This merger plan threatens to create a Death Star — the ultimate superweapon that cannot be penetrated. This means unlike its predecessor bankruptcies in which the attorneys could go after a sole surviving party, Chemours inevitable bankruptcy won’t have a single responsible party to sue for fraudulent conveyance of Chemours.

You can find the entire Citron report on Chemours here.

http://www.citronresearch.com/chemours-is-a-bankruptcy-waiting-to-happen-chemours-was-purposely-designed-for-bankruptcy/

Shares of Chemours have dropped 7.4% to $8.15 at 2:49 p.m. today, while DuPont has gained 1.8% to $67.61, and Dow Chemical has risen 1.1% to $52.12.

http://blogs.barrons.com/stockstowatchtoday/2016/06/02/chemours-dupont-spinoff-was-purposely-designed-for-bankruptcy-citron-says/

Chemours Strongly Refutes Citron Report (6/02/16)

WILMINGTON, Del., June 2, 2016 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC) strongly refutes the report by Citron Research issued today.

Chemours, a global chemistry company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, was created to build on its fundamental strengths.

Upon becoming an independent company less than one year ago, Chemours immediately launched a five-point transformation plan to improve Adjusted EBITDA by $500 million over 2015 levels and reduce its leverage ratio to approximately three times in 2017. Chemours continues to execute on all aspects of its plan by reducing cost, optimizing its portfolio, growing market positions, refocusing investments and enhancing its organization. The company has taken swift and decisive action under this plan and has already delivered significant cost reductions while strengthening its liquidity position. Chemours is making major investments in key growth initiatives, and continues to progress the strategic review of its Chemical Solutions business.

The company reaffirms its 2016 outlook of Adjusted EBITDA above the 2015 performance, generating modestly positive free cash flow. This includes the expectation of $200 million of cost savings realized in 2016.

Information about Chemours businesses, market positions and financial performance is available on Chemours.com.

About The Chemours Company
The Chemours Company (NYSE: CC) helps create a colorful, capable and cleaner world through the power of chemistry. Chemours is a global leader in titanium technologies, fluoroproducts and chemical solutions, providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. Chemours ingredients are found in plastics and coatings, refrigeration and air conditioning, mining and oil refining operations and general industrial manufacturing. Our flagship products include prominent brands such as Teflon™, Ti-Pure™, Krytox™, Viton™, Opteon™ and Nafion™. Chemours has approximately 8,100 employees across 35 manufacturing sites serving more than 5,000 customers in North America, Latin America, Asia-Pacific and Europe. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC. For more information please visit chemours.com or follow Chemours on Twitter at @chemours.

http://www.prnewswire.com/news-releases/chemours-strongly-refutes-citron-report-300279108.html

Once Again CC On The Move Back Up, Now 6 And Soon 12, Great Time To Buy . . imo.

CC On The Move Back Up . . Good Time To Buy . . imo.

$CC recent news/filings

bearish 6.01

## source: finance.yahoo.com

Thu, 19 Nov 2015 14:07:38 GMT ~ CHEMOURS CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/151119/cc8-k.html
*********************************************************

Thu, 19 Nov 2015 13:02:00 GMT ~ 8:02 am Chemours to sell its aniline facility in Beaumont, Texas to Dow Chemical (DOW) for ~$140 mln in cash


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#cc
*********************************************************

Thu, 19 Nov 2015 13:00:00 GMT ~ Chemours Signs Definitive Agreement to Sell Aniline Facility

[PR Newswire] - WILMINGTON, Del., Nov. 19, 2015 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC), a global chemical company with leading market positions in titanium technologies, fluoroproducts ...

read full: http://finance.yahoo.com/news/chemours-signs-definitive-agreement-sell-130000058.html
*********************************************************

Tue, 17 Nov 2015 20:52:00 GMT ~ Low P/E Stocks Ready for a Turnaround?


read full: http://www.investopedia.com/stock-analysis/cotd/111715/low-pe-stocks-ready-turnaround-cc-nsr-sdlp.aspx?partner=YahooSA
*********************************************************

Tue, 17 Nov 2015 18:34:00 GMT ~ Chemours Breaks Ground for World's First Full-Scale Production of HFO-1336mzz

[PR Newswire] - WILMINGTON, Del., Nov. 17, 2015 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC), a global chemical company with leading market positions in titanium technologies, fluoroproducts ...

read full: http://finance.yahoo.com/news/chemours-breaks-ground-worlds-first-183400538.html
*********************************************************

$CC charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CC company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CC/company-info
Ticker: $CC
OTC Market Place: Not Available
CIK code: not found
Company name: Chemours Company (The)
Incorporated In:


$CC share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$CC extra dd links

Company name: Chemours Company (The)
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CC/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CC/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CC+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CC+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CC+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CC/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CC/news - http://finance.yahoo.com/q/h?s=CC+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CC/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CC/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CC/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CC/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CC/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CC/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CC/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CC/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CC+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CC
DTCC (dtcc.com): http://search2.dtcc.com/?q=Chemours+Company+%28The%29&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Chemours+Company+%28The%29
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Chemours+Company+%28The%29&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CC/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CC
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CC/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CC/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CC/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CC/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CC/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CC/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CC/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CC&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CC
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CC/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CC+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CC+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CC
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CC
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CC+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CC/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CC+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CC.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CC
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CC/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CC/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CC/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CC/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CC
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CC
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CC:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CC
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CC



$CC DD Notes ~ http://www.ddnotesmaker.com/CC

CC down 60% from Jun 2015 spin date, even after today's pop: #msg-117517724.

thanks mick